WO2017151655A1 - Cancer immune-based therapy - Google Patents
Cancer immune-based therapy Download PDFInfo
- Publication number
- WO2017151655A1 WO2017151655A1 PCT/US2017/020004 US2017020004W WO2017151655A1 WO 2017151655 A1 WO2017151655 A1 WO 2017151655A1 US 2017020004 W US2017020004 W US 2017020004W WO 2017151655 A1 WO2017151655 A1 WO 2017151655A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- cells
- tumor
- million
- deglycosylated
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 304
- 201000011510 cancer Diseases 0.000 title claims description 166
- 238000009169 immunotherapy Methods 0.000 title description 3
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 179
- 230000006023 anti-tumor response Effects 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 213
- 238000000034 method Methods 0.000 claims description 67
- 239000002671 adjuvant Substances 0.000 claims description 46
- 238000011282 treatment Methods 0.000 claims description 38
- 229940121672 Glycosylation inhibitor Drugs 0.000 claims description 32
- 239000013592 cell lysate Substances 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 26
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 21
- 150000001720 carbohydrates Chemical group 0.000 claims description 20
- 102000004190 Enzymes Human genes 0.000 claims description 16
- 108090000790 Enzymes Proteins 0.000 claims description 16
- 230000004614 tumor growth Effects 0.000 claims description 15
- 238000011161 development Methods 0.000 claims description 13
- 239000012062 aqueous buffer Substances 0.000 claims description 11
- 230000022811 deglycosylation Effects 0.000 claims description 10
- 239000007800 oxidant agent Substances 0.000 claims description 9
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 150000004676 glycans Chemical class 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 8
- 238000011275 oncology therapy Methods 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 229940088710 antibiotic agent Drugs 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 230000002934 lysing effect Effects 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 4
- 208000037819 metastatic cancer Diseases 0.000 claims description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 3
- 230000002596 correlated effect Effects 0.000 claims description 2
- 230000006735 deficit Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 238000013459 approach Methods 0.000 abstract description 6
- 102000004169 proteins and genes Human genes 0.000 abstract description 6
- 229940021747 therapeutic vaccine Drugs 0.000 abstract description 5
- 125000000837 carbohydrate group Chemical group 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 description 106
- 210000004379 membrane Anatomy 0.000 description 34
- 239000012528 membrane Substances 0.000 description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- 201000010099 disease Diseases 0.000 description 29
- 241000282472 Canis lupus familiaris Species 0.000 description 25
- 238000011534 incubation Methods 0.000 description 20
- 238000011081 inoculation Methods 0.000 description 19
- 239000006166 lysate Substances 0.000 description 17
- 239000000427 antigen Substances 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 230000001394 metastastic effect Effects 0.000 description 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 14
- 201000001441 melanoma Diseases 0.000 description 13
- 241000282465 Canis Species 0.000 description 12
- 230000018109 developmental process Effects 0.000 description 12
- 230000028993 immune response Effects 0.000 description 11
- 210000000822 natural killer cell Anatomy 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000000735 allogeneic effect Effects 0.000 description 10
- 230000013595 glycosylation Effects 0.000 description 10
- 238000006206 glycosylation reaction Methods 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- 230000001771 impaired effect Effects 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 108090000288 Glycoproteins Proteins 0.000 description 7
- 102000003886 Glycoproteins Human genes 0.000 description 7
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 7
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 7
- 108010006232 Neuraminidase Proteins 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000001900 immune effect Effects 0.000 description 7
- 210000001165 lymph node Anatomy 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 6
- 102000005348 Neuraminidase Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 210000003754 fetus Anatomy 0.000 description 6
- 238000003306 harvesting Methods 0.000 description 6
- 229940121354 immunomodulator Drugs 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 210000004291 uterus Anatomy 0.000 description 6
- 108090001090 Lectins Proteins 0.000 description 5
- 102000004856 Lectins Human genes 0.000 description 5
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 235000013601 eggs Nutrition 0.000 description 5
- 150000002339 glycosphingolipids Chemical class 0.000 description 5
- 230000037451 immune surveillance Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 239000002955 immunomodulating agent Substances 0.000 description 5
- 239000002523 lectin Substances 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 4
- 108010037897 DC-specific ICAM-3 grabbing nonintegrin Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000004989 O-glycosylation Effects 0.000 description 4
- 230000006037 cell lysis Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000036755 cellular response Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000011221 initial treatment Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 210000000115 thoracic cavity Anatomy 0.000 description 4
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical class CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 241000289695 Eutheria Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 108010093031 Galactosidases Proteins 0.000 description 3
- 102000002464 Galactosidases Human genes 0.000 description 3
- 102100029880 Glycodelin Human genes 0.000 description 3
- 101000585553 Homo sapiens Glycodelin Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 3
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 3
- 230000004988 N-glycosylation Effects 0.000 description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 description 3
- 230000033289 adaptive immune response Effects 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 108010014507 erythroagglutinating phytohemagglutinin Proteins 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000002414 glycolytic effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007951 isotonicity adjuster Substances 0.000 description 3
- -1 kifunensin Chemical compound 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000008774 maternal effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 2
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 2
- 208000036566 Erythroleukaemia Diseases 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 102000007563 Galectins Human genes 0.000 description 2
- 108010046569 Galectins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 description 2
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical compound CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 description 2
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 2
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 208000021841 acute erythroid leukemia Diseases 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001998 anti-microbiological effect Effects 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 229940037642 autologous vaccine Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 150000002270 gangliosides Chemical class 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 230000006095 glypiation Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 108091008042 inhibitory receptors Proteins 0.000 description 2
- 108010085650 interferon gamma receptor Proteins 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000000503 lectinlike effect Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000004373 mandible Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
- SKOZFDIGKDPQBO-QMIVOQANSA-N n-[(2s,3r,4r,5r,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-phenylmethoxyoxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OCC1=CC=CC=C1 SKOZFDIGKDPQBO-QMIVOQANSA-N 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 210000004882 non-tumor cell Anatomy 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229940034080 provenge Drugs 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 229960000714 sipuleucel-t Drugs 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 229940022511 therapeutic cancer vaccine Drugs 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-KVTDHHQDSA-N (2r,3r,4r)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@@H](O)[C@H]1O JNYAEWCLZODPBN-KVTDHHQDSA-N 0.000 description 1
- LXBIFEVIBLOUGU-KVTDHHQDSA-N (2r,3r,4r,5r)-2-(hydroxymethyl)piperidine-3,4,5-triol Chemical compound OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-KVTDHHQDSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- XBNDESPXQUOOBQ-LSMLZNGOSA-N (2r,3s)-4-[[(2s)-1-[[2-[[(2s)-1-[[2-[[(2r,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-[(3s,9ar)-1,4-dioxo-3,6,7,8,9,9a-hexahydro-2h-pyrido[1,2-a]pyrazin-3-yl]ethyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino]-3-amino-1-oxobutan-2-yl]amino]-2-oxoethyl]am Chemical compound CCC(C)CCCCC\C=C\CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)C(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H]([C@H](C)N)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)[C@H]1C(=O)N2CCCC[C@@H]2C(=O)N1 XBNDESPXQUOOBQ-LSMLZNGOSA-N 0.000 description 1
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical group O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 1
- DRHXTSWSUAJOJZ-FMDGEEDCSA-N (3ar,5r,6s,7r,7ar)-5-(hydroxymethyl)-2-methyl-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(C)=N[C@H]2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]2O DRHXTSWSUAJOJZ-FMDGEEDCSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 1
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 1
- UMHYVXGZRGOICM-AUYXYSRISA-N 2-[(z)-octadec-9-enoyl]oxypropyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC\C=C/CCCCCCCC UMHYVXGZRGOICM-AUYXYSRISA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QWVRTSZDKPRPDF-UHFFFAOYSA-N 5-(piperidin-1-ylmethyl)-3-pyridin-3-yl-5,6-dihydro-2h-1,2,4-oxadiazine Chemical compound C1CCCCN1CC(N=1)CONC=1C1=CC=CN=C1 QWVRTSZDKPRPDF-UHFFFAOYSA-N 0.000 description 1
- AIQMLBKBQCVDEY-UHFFFAOYSA-N 7-epi-australine Natural products OC1CCN2C(CO)C(O)C(O)C21 AIQMLBKBQCVDEY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229940124321 AIDS medicine Drugs 0.000 description 1
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 108700023418 Amidases Proteins 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- AIQMLBKBQCVDEY-OZRXBMAMSA-N Australine Chemical compound O[C@H]1CCN2[C@H](CO)[C@@H](O)[C@H](O)[C@H]21 AIQMLBKBQCVDEY-OZRXBMAMSA-N 0.000 description 1
- AIQMLBKBQCVDEY-FMGWEMOISA-N Australine Natural products O[C@@H]1CCN2[C@@H](CO)[C@H](O)[C@H](O)[C@H]21 AIQMLBKBQCVDEY-FMGWEMOISA-N 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 description 1
- JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 101000583741 Clostridium perfringens Sialidase Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000000970 DNA cross-linking effect Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 102000000802 Galectin 3 Human genes 0.000 description 1
- 108010001517 Galectin 3 Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108010081520 Glycodelin Proteins 0.000 description 1
- 102000004240 Glycodelin Human genes 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 description 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
- 101000955067 Homo sapiens WAP four-disulfide core domain protein 2 Proteins 0.000 description 1
- 241000701096 Human adenovirus 7 Species 0.000 description 1
- 241000193096 Human adenovirus B3 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- YCPLHXLUOSXDJD-WNRNVDISSA-N N-[(5S,6R,7R,8R)-6,7-dihydroxy-5-(hydroxymethyl)-2-(2-phenylethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-8-yl]-2-methylpropanamide Chemical compound CC(C)C(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)n2cc(CCc3ccccc3)nc12 YCPLHXLUOSXDJD-WNRNVDISSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- RMINQIRDFIBNLE-NNRWGFCXSA-N O-[N-acetyl-alpha-neuraminyl-(2->6)-N-acetyl-alpha-D-galactosaminyl]-L-serine Chemical compound O1[C@H](OC[C@H](N)C(O)=O)[C@H](NC(=O)C)[C@@H](O)[C@@H](O)[C@H]1CO[C@@]1(C(O)=O)O[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C1 RMINQIRDFIBNLE-NNRWGFCXSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241001524178 Paenarthrobacter ureafaciens Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100038551 Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase Human genes 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 description 1
- 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 description 1
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 description 1
- 102100028755 Sialidase-2 Human genes 0.000 description 1
- 102000036646 Signalosomes Human genes 0.000 description 1
- 108091007411 Signalosomes Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102100038965 WAP four-disulfide core domain protein 2 Human genes 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- PBLNJFVQMUMOJY-JXZOILRNSA-N [(z)-[(3r,4r,5s,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-ylidene]amino] n-phenylcarbamate Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O\C1=N/OC(=O)NC1=CC=CC=C1 PBLNJFVQMUMOJY-JXZOILRNSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960002648 alanylglutamine Drugs 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- SRHNADOZAAWYLV-XLMUYGLTSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O SRHNADOZAAWYLV-XLMUYGLTSA-N 0.000 description 1
- NIGUVXFURDGQKZ-UQTBNESHSA-N alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O NIGUVXFURDGQKZ-UQTBNESHSA-N 0.000 description 1
- 102000005922 amidase Human genes 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 108010079465 amphomycin Proteins 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 210000003503 anal sac Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000000040 apocrine gland Anatomy 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- WXNRAKRZUCLRBP-UHFFFAOYSA-N avridine Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 description 1
- 229950010555 avridine Drugs 0.000 description 1
- UPAZUDUZKTYFBG-HNPUZVNISA-N azane [(2S,3R,4R,5S,6R)-2,5-dihydroxy-6-[[(2R,3R,4R,5S,6R)-6-(hydroxymethyl)-5-phosphonooxy-3-[[(3R)-3-tetradecanoyloxytetradecanoyl]amino]-4-[(3R)-3-tetradecanoyloxytetradecanoyl]oxyoxan-2-yl]oxymethyl]-3-[[(3R)-3-hydroxytetradecanoyl]amino]oxan-4-yl] (3R)-3-hydroxytetradecanoate Chemical compound [NH4+].CCCCCCCCCCCCCC(=O)O[C@H](CCCCCCCCCCC)CC(=O)N[C@H]1[C@H](OC[C@H]2O[C@H](O)[C@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H]2O)O[C@H](CO)[C@@H](OP(O)([O-])=O)[C@@H]1OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC UPAZUDUZKTYFBG-HNPUZVNISA-N 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- UZZNPRAXUPVEEY-HRVOHQSGSA-N beta-D-GalpNAc-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc Chemical group O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O UZZNPRAXUPVEEY-HRVOHQSGSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 210000003785 decidua Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 208000024312 invasive carcinoma Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 108010011519 keratan-sulfate endo-1,4-beta-galactosidase Proteins 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004997 mammalian reproductive system Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940115256 melanoma vaccine Drugs 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000011169 microbiological contamination Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- UQRORFVVSGFNRO-UTINFBMNSA-N miglustat Chemical compound CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO UQRORFVVSGFNRO-UTINFBMNSA-N 0.000 description 1
- 229960001512 miglustat Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000000897 modulatory effect Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- AFFLGGQVNFXPEV-UHFFFAOYSA-N n-decene Natural products CCCCCCCCC=C AFFLGGQVNFXPEV-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000002888 oleic acid derivatives Chemical class 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000028742 placenta development Effects 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940010310 propylene glycol dioleate Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000030634 protein phosphate-linked glycosylation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940038774 squalene oil Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 210000000242 supportive cell Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- FXUAIOOAOAVCGD-UHFFFAOYSA-N swainsonine Natural products C1CCC(O)C2C(O)C(O)CN21 FXUAIOOAOAVCGD-UHFFFAOYSA-N 0.000 description 1
- FXUAIOOAOAVCGD-FKSUSPILSA-N swainsonine Chemical compound C1CC[C@H](O)[C@H]2[C@H](O)[C@H](O)CN21 FXUAIOOAOAVCGD-FKSUSPILSA-N 0.000 description 1
- 229960005566 swainsonine Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229940030325 tumor cell vaccine Drugs 0.000 description 1
- 230000037455 tumor specific immune response Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
Definitions
- the present disclosure relates to cancer therapy, more particularly to a therapeutic vaccine that triggers a therapeutic antitumor response.
- Cancer is an abnormal proliferation of cells, and in many cases their dissemination, that can occur virtually anywhere in any multicellular organism (1).
- the corresponding estimated number of deaths due to cancer was 595,690.
- 42% of human males and 38% of all females will eventually develop cancer during their lifetime (2).
- the same statistical data indicate that 22.6% of men and 19.1% of females will eventually succumb to cancer (2).
- Classical immunization strategies have failed to block the development of metastatic cancer, and in some cases tend to actually decrease survival (3). All therapeutic cancer vaccines, with one possible exception (Provenge, sipuleucel-T) have not had any positive effect on survival (4).
- lymphocytes act as sentinels that recognize specific tumor associated antigens that arise from spontaneous mutations.
- Tumor associated antigens are also often referred to as neoantigens (10).
- Neoantigens enable the efficient immune destruction of tumor cells as they emerge due to mutation.
- spontaneous fatal tumors arise because: (i) malignant cells had somehow managed to escape immunosurveillance; or (ii) the immune system was compromised in some way that inhibited anti-tumor cell responses (9).
- mice deficient in specific key immune activating molecules were also shown to have higher incidences of carcinogen-induced tumors and spontaneous epithelial carcinomas (13). These results were consistent with immunosurveillance that targets tumor cells for destruction, preventing the development of lethal cancers. A plethora of evidence now firmly supports the immune surveillance model for the prevention of cancer (14, 15).
- Burnet's model immediately suggested that tumor cell vaccines should be useful for preventing the development of cancer by stimulating the immune system.
- immunization with either syngeneic or allogeneic tumor cell lysates did not prevent the development of spontaneous cancer in either humans or animal models (16, 17).
- vaccinologists suggested that tumor antigens would be more effective if administered as part of a therapeutic rather than a preventative vaccine (18).
- the results with therapeutic vaccines have also been poor (3).
- Canvaxin a therapeutic human melanoma vaccine that was composed of tumor cell lysates from three allogeneic melanoma cell lines combined with a powerful adjuvant ⁇ Bacillus Calmette- Guerin; BCG) (19).
- BCG Calmette- Guerin
- the fetus is completely foreign if development occurs in the uterus of an unrelated surrogate mother facilitated by human IVF. How female placental mammals (eutherians) can accommodate the foreign fetus has been a major question since this enigma was proposed over sixty years ago (22- 27).
- Spermatogenesis is initiated in human males during puberty, long after the period of thymic education (30).
- Sperm proteins are specifically expressed for the first time during the onset of puberty, suggesting that they are antigenic. Such proteins are often referred to as either autoantigens or neoantigens (31, 32).
- autoantigens or neoantigens 31, 32
- tolerizing factors are expressed in the human male urogenital tract and seminal plasma that likely block immune responses directed against sperm autoantigens (33).
- human seminal plasma factors do not enter the uterus, but sperm have complete access to the female urogenital tract.
- HLA class I negative human sperm from NK cell A pathway for the protection of HLA class I negative human sperm from NK cell was proposed in 1996 as a component of the Hu-FEDS model.
- HLA class I negative K562 erythroleukemia cells are efficiently lysed in NK cell cytotoxicity assays (35).
- K562 cells become completely resistant to NK cell lysis if the level of expression of a specific carbohydrate sequence known as the biantennary bisecting type (BBSCT) N-glycan is elevated on their surface (36, 37).
- BBSCT biantennary bisecting type
- TACAs tumor associated carbohydrate antigens
- SLEX and Lewis y sequences are attached to all three major classes of glycoconjugates on human tumor cells (N-glycans, O-glycans, glycosphingolipids) (44, 47, 48).
- the Lewis y sequence was previously shown to be a useful target in antibody-directed radioimmunotherapy in dogs (49).
- BBSCT N-glycan expression is also often elevated on the surface of tumor cells arising from different organs (50)
- TACAs include glycosphingolipids (globo H, GM2, GD2, GD3,) and antigens attached to N-glycans, O-glycans or glycosphingolipids (H blood group, Lewis 3 , sialyl-Lewis a , Tn, sialyl-Tn) (47).
- melanoma cells overexpress gangliosides GM2, GD2, and GD3 (51).
- GD3 is a ligand for Siglec-7, another ITIM type receptor on NK cells that inhibits lytic responses (52).
- Metastatic human melanoma cells also present high levels of linear polylactosamine type sequences on their N-glycans that are undetectable in normal melanocytes (53). Similarly, elevated levels of polylactosamines are also observed on invasive colorectal, pancreatic, breast, lung, hepatocellular, ovarian and papillary cancer, but not their progenitor cells. Linear polylactosamine sequences bind specifically to galectins. Galectins have been shown to induce substantial modulatory effects on the human immune response (54, 55). [0016] As noted earlier, glycodelin-A is a glycoprotein with substantial immune modulatory activity that is expressed in the pregnant human uterus (56).
- a specific CFG that has been implicated in mediating its biological activity is the fucosylated lacdiNAc sequence (57). Recent analyses indicate that this sequence is highly expressed on poorly differentiated human colorectal cancer cells with high metastatic potential (48). In summary, many and perhaps all of the CFGs that protect human gametes and the developing eutherian in utero from the maternal immune response are also being deployed by mammalian tumor cells to protect them from immune surveillance (58).
- the present disclosure provides a novel therapeutic vaccine approach that triggers a therapeutic antitumor response. More specifically, according to one embodiment of the disclosure, the method may comprise the step of inoculating of a subject (human or other mammal) with autologous deglycosylated tumor cell lysates to evoke an immune-based antitumor response.
- the potency of the lysates is inversely correlated with the stage of the cancer, the age of the subject, the immune status of said subject (the cancer patient), or a combination of these factors.
- the method may comprise the step of inoculating of a healthy subject (human or other mammal) with syngeneic or HLA class I negative deglycosylated metastatic tumor cell lysates to evoke a durable antitumor response directed against neoantigens to prevent or greatly impede the development of aggressive cancer.
- This immunization approach may enable all humans and other mammals to resist the development of metastatic cancer for as long as immunocompetence is maintained. Generally speaking, immunocompetence is maintained in the great majority of humans until at least age 80, unless the person is a smoker, engages in excessive alcohol consumption, or suffers from a known genetic or acquired immunodeficiency.
- One embodiment of the present disclosure provides methods of preparing an adjuvanted, deglycosylated autologous tumor vaccine and treatment that may be derived from the tumor cells of a patient.
- the method comprises harvesting and isolating cancer cells from patient cancers for incubation with one or more deglycosylation agents and/or inhibitors wherein after the incubation a majority of the cancer cell membrane is deglycosylated.
- deglycosylated refers to the disruption of glycolytic linkages, inhibition of forming glycolytic linkages, or disruption and inhibition of forming glycolytic linkages on at least a majority of the cancer cell membrane.
- Deglycosylation disrupts the carbohydrate functional groups (CFGs) and subsequent glycan shielding to expose the neoantigens and thereby permit the immune system to detect and attack cancer cells once the composition is administered to the patient.
- the method also comprises combining deglycosylated cancer cell lysate with at least one additional component selected from the group consisting of pharmaceutically-acceptable carriers, adjuvants, diluents, preservatives, antibiotics, and combinations thereof.
- the cancer cells are tumor cells and in other forms, the cancer cells are from liquid cancers such as leukemia. It is understood that when "tumor cells" are referenced herein, it also encompasses cells from liquid cancers.
- the patient refers to an animal that has presented with cancer.
- the patient may be a mammal, and in some embodiments, the patient may be a human.
- a patient may be a livestock animal (horse, cow, pig, sheep, etc.) or a companion animal (dog, cat, etc.).
- the patient may be canine.
- the patient may have cancer at any stage of disease progression.
- the patient may have Stage I-IV cancer.
- the patient has Stage I-III cancer.
- the patient has Stage I-II cancer.
- the patient has Stage I cancer.
- the cancer may be a primary cancer, a metastases, or primary cancer and metastases.
- the cancer may be a solid cancer.
- the cancer may be a liquid cancer.
- Non-limiting examples of cancer types include carcinomas, sarcomas, lymphomas, leukemias, myelomas and mixed types (e.g., blastomas).
- cancer cells may be harvested from a solid tumor, a metastatic node or a solid tumor and a metastatic node, or a liquid cancer.
- a harvested tumor cell source may be less than about 0.2 cm 3 to at least about 20 cm 3 or greater, at least about 2 cm 3 to at least about 18 cm 3 or greater, at least about 3 cm3 to at least about 15 cm 3 or greater, at least about 4 cm 3 to at least about 12 cm 3 or greater, at least about 5 cm 3 to at least about 10 cm 3 or greater, or at least about 6 cm 3 to at least about 8 cm 3 or greater.
- a harvested tumor cell source may be at least about 0.2 cm 3 or greater, at least about 0.3 cm 3 or greater, at least about 0.4 cm 3 or greater, at least about 0.5 cm 3 or greater, at least about 1 cm 3 or greater, at least about 2 cm 3 or greater, at least about 3 cm 3 or greater, at least about 4 cm 3 or greater, at least about 5 cm 3 or greater, at least about 6 cm 3 or greater, at least about 7 cm 3 or greater, at least about 8 cm 3 or greater, at least about 9 cm 3 or greater, at least about 10 cm 3 or greater, at least about 11 cm 3 or greater, at least about 12 cm 3 or greater, at least about 13 cm 3 or greater, at least about 14 cm 3 or greater, at least about 15 cm 3 or greater, at least about 16 cm 3 or greater, at least about 17 cm 3 or greater, at least about 18 cm 3 or greater, at least about 19 cm 3 or greater, or at least about 20 cm 3 or greater.
- a harvested tumor cell source may be at least about 0.2 cm 3 to about 0.3 cm 3 or greater, at least about 0.3 cm 3 to about 0.4 cm 3 or greater, at least about 0.4 cm 3 to about 0.5 cm 3 or greater, at least about 0.5 cm 3 to about 1 cm 3 or greater, at least about 1 cm 3 to about 2 cm 3 or greater, at least about 2 cm 3 to about 3 cm 3 or greater, at least about 3 cm 3 to about 4 cm 3 or greater, at least about 4 cm 3 to about 5 cm 3 or greater, at least about 5 cm 3 to about 6 cm 3 or greater, at least about 6 cm 3 to about 7 cm 3 or greater, at least about 7 cm 3 to about 8 cm 3 or greater, at least about 8 cm 3 to about 9 cm 3 or greater, at least about 9 cm 3 to about 10 cm 3 or greater, at least about 10 cm 3 to about 11 cm 3 or greater, at least about 11 cm 3 to about 12 cm 3 or greater, at least about 12 cm 3 to about 13 cm 3 or greater, at least about 13 cm 3 to about 14 cm 3
- a harvested tumor cell source may have enough cells to be isolated and amplified.
- the harvested tumor cell source should have between at least about 0.5 million cells to at least about 60 million cells or greater, at least about 5 million cells to at least about 55 million cells or greater, at least about 10 million cells to at least about 50 million cells or greater, at least about 15 million cells to at least about 50 million cells or greater, at least about 20 million cells to at least about 50 million cells or greater, at least about 25 million cells to at least about 50 million cells or greater, at least about 30 million cells to at least about 40 million cells or greater, or at least about 45 million cells to at least about 45 million cells or greater.
- tumor cells may be expanded in culture to obtain at least about 0.5 million cells, at least about 1 million cells, at least about 5 million cells, at least about 10 million cells, at least about 15 million cells, at least about 20 million cells, at least about 25 million cells, at least about 30 million cells, 35 million cells, at least about 40 million cells, at least about 45 million cells, at least about 50 million cells, at least about 55 million cells, at least about 60 million cells, or greater.
- tumor cells may be expanded in culture to obtain at least about 0.5 million cells to at least about 1 million cells, at least about 1 million cells to at least about 5 million cells, at least about 5 million cells to at least about 10 million cells, at least about 10 million cells to at least about 15 million cells, at least about 15 million cells to at least about 20 million cells, at least about 20 million cells to at least about 25 million cells, at least about 25 million cells to at least about 30 million cells, at least about 30 million cells to at least about 35 million cells, 35 million cells to at least about 40 million cells, at least about 40 million cells to at least about 45 million cells, at least about 45 million cells to at least about 50 million cells, at least about 50 million cells to at least about 55 million cells, at least about 55 million cells to at least about 60 million cells.
- a method of the present disclosure compromises incubating tumor cells with one or more deglycosylating agents and/or glycosylation inhibitors, wherein after the incubation a majority of tumor cell membrane is deglycosylated.
- a majority or at least 50% of the tumor cell membrane is deglycosylated.
- at least about 55% or more of the tumor cell membrane is deglycosylated.
- at least about 65% or more of the tumor cell membrane is deglycosylated.
- at least about 75% or more of the tumor cell membrane is deglycosylated.
- at least about 85% or more of the tumor cell membrane is deglycosylated.
- At least about 95% or more of the tumor cell membrane is deglycosylated.
- at least about 55% to 95% or greater, at least about 65% to 95% or greater, at least about 75% to 95% or greater, at least about 85%) to 95% or greater, or at least about 90% to 95% or greater of tumor cell membrane is deglycosylated.
- the percentage of tumor cell membrane that is deglycosylated refers to the percentage of CFGs or glycan shield that is disrupted, destroyed, or prevented from forming.
- tumor cells may maintain viability after incubation with one or more deglycosylating agents and/or glycosylation inhibitors.
- tumor cells maintain at least about 85% or greater, at least about 90% or greater, at least about 95% or greater, at least about 98% or greater, viability after incubation with one or more deglycosylating agents and/or glycosylation inhibitors.
- the membrane of the tumor cell maintains integrity after incubation with one or more deglycosylating agents and/or glycosylation inhibitors.
- the membrane of the tumor cell maintains at least about 85% or greater, at least about 90% or greater, at least about 95% or greater, at least about 98% or greater, integrity after incubation with one or more deglycosylating agents and/or glycosylation inhibitors in comparison to a tumor cell that has not been incubated with one or more deglycosylation agents and/or glycosylation inhibitors.
- membrane permeability of tumor cells after incubation with one or more deglycosylation agents and/or glycosylation inhibitors is increased compared to membranes of tumors cells not incubated with one or more deglycosylation agents and/or glycosylation inhibitors.
- membrane permeability may be increased at least about 10% or greater, at least about 15%> or greater, at least about 20% or greater, at least about 25% or greater, at least about 30%> or greater, at least about 35% or greater, at least about 40% or greater, at least about 45% or greater, at least about 50% or greater, at least about 55% or greater, at least about 60%) or greater, at least about 65% or greater, at least about 70% or greater, at least about 75%) or greater, at least about 80% or greater, at least about 85% or greater, at least about 90% or greater, at least about 95% or greater, or at least about 98% or greater compared to cell membranes of tumor cells not incubated with one or more deglycosylation agents and/or glycosylation inhibitors.
- the cell membrane permeability of tumor cells after incubation with one or more deglycosylation agents and/or glycosylation inhibitors may be increased at least about 10% to 98% or greater, at least 25% to 98% or greater, or at least 50% to 95%) or greater compared to cell membranes of tumor cells not incubated with one or more deglycosylation agents and/or glycosylation inhibitors.
- N-linked glycosylation of the tumor cell membrane may be disrupted.
- O-linked glycosylation of the tumor cell membrane may be disrupted.
- C-linked glycosylation of the tumor cell membrane may be disrupted.
- glypiation of the tumor cell membrane may be disrupted.
- O-linked glycosylation may be disrupted.
- multiple glycosidic linkages on the tumor cell membrane may be disrupted comprising of N-, 0-, and C-linked glycosylation, glypiation, and phosphoglycosylation.
- deglycosylating agents may be one or more deglycosylating enzymes.
- a "deglycosylating enzyme” refers to an enzyme that modifies or removes glycans from glycoproteins presented on the tumor cell membrane.
- one or more deglycosylating enzymes may be a glycoside hydrolase with an EC number of EC 3.2.1.
- deglycosylating enzymes may be a neuraminidase with an EC number of EC 3.2.1.18.
- deglycosylating enzymes may be a galactosidase with an EC number of EC 3.2.1.23.
- deglycosylating enzymes may be an exoglycosidase with an EC number of EC 3.2.1.25. In another embodiment, deglycosylating enzymes may be an endoglycosidase with an EC number of EC 3.2.1.96. In another embodiment, deglycosylating enzymes may be an O-Glycosidase with an EC number of EC 3.2.1.97. In yet another embodiment, deglycosylating enzymes may be an amidase with an EC number of EC 3.5.1.52.
- a deglycosylating enzyme may be selected from the non-limiting group consisting of a Clostridium perfringens neuraminidase, Vibrio cholerae neuraminidase, Arthrobacter ureafaciens neuraminidase, Streptococcus pneumonia neuraminidase, Enterococcus faecalis O-Glycosidase, Streptococcus pneumonia ⁇ 1-4 galactosidase, recombinant endo-P-galactosidase, and recombinant PNGase F.
- a Clostridium perfringens neuraminidase Vibrio cholerae neuraminidase
- Arthrobacter ureafaciens neuraminidase Arthrobacter ureafaciens neuraminidase
- Streptococcus pneumonia neuraminidase Enterococcus faecali
- the amount of the one or more deglycosylating enzymes used is generally determined by the volume of tumor cells to be deglycosylated.
- tumor cells may be incubated with at least two, at least three, at least four, at least five, or at least six or more distinct deglycosylating enzymes.
- deglycosylating agents may be one or more glycosylation inhibitors.
- a "glycosylation inhibitor” refers to a compound that blocks glycosylation of proteins on the tumor cell membrane.
- one or more glycosylation inhibitors may be a natural product.
- one or more glycosylation inhibitors may be a synthesized product.
- one or more glycosylation inhibitors may interfere with the steps involved in the process of glycosylation.
- one or more glycosylation inhibitors may inhibit N-glycosylation synthesis.
- one or more glycosylation inhibitors may inhibit O-glycosylation synthesis.
- one or more glycosylation inhibitors may inhibit glycosphingolipid synthesis. In another embodiment, one or more glycosylation inhibitors may block glycosyltransferase activity. In another embodiment, one or more glycosylation inhibitors may block glucosylceramide synthetase activity. In another embodiment, one or more glycosylation inhibitors may belong to a class of nucleoside antibiotics. In another embodiment, one or more glycosylation inhibitors may be a plant alkaloid.
- a glycosylation inhibitor may be selected from the non-limiting group consisting of tunicamycin, amphomycin, castanospermine, deoxynojirimycin, australine, swainsonine, deoxymannojirimycin, kifunensin, benzyl 2-acetamido-2-deoxy-a-D-galactopyranoside, D-threo- l-phenyl-2-decanoylamino-3-morpholino-l-propanol, PUGNAc, NAG-thiazoline, GlcNAcstatin, N-butyldeoxynojirimycin, and Neu5Ac-2-ene.
- tumor cells may be incubated with at least two, at least three, at least four, at least five, or at least six or more glycosylation inhibitors.
- one or more deglycosylating enzymes may be combined with one or more glycosylation inhibitors as described above and each are referred to herein as "deglycosylating agents”.
- cells may be suspended in cell culture media containing one or more deglycosylating agents and/or glycosylation inhibitors.
- the tumor cells may be incubated with one or more deglycosylating agents and/or glycosylation inhibitors for a time sufficient to deglycosylate the tumor cell membrane as described above.
- the incubation period may be for at least about 30 minutes, 1 hour, 2 hours, 3 hours, at least 4 hours, at least 5 hours, or greater, as well as the ranges created by two or more of these options (i.e. 30 minutes to 5 hours, 2 hours to 4 hours, 1 hour to 5 hours, etc.).
- the tumor cells may be incubated with one or more deglycosylating agents and/or glycosylation inhibitors at an appropriate temperature sufficient to permit deglycosylation of the tumor cell membrane as described above.
- the incubation temperature may be about 12°C to 42°C, 15°C to 42°C, 20°C to 42°C, 25°C to 42°C, 32°C to 42°C, at about 34°C to 40°C, or at about 36°C to 38°C.
- the incubation period may be stopped by washing the tumor cells in order to remove the deglycosylating agents and/or glycosylation inhibitors from the tumor cells.
- the aqueous buffer may be sodium phosphate buffer.
- the aqueous buffer may contain a solute.
- the solute may be at least about 0.3 M to 0.1 M, at least about 0.2 M to 0.15 M, or at least about 0.15 M of a chloride, preferably sodium chloride.
- the pH of the aqueous buffer may be about 4 to 7, may be about 5.5 to 6.5, or may be at least about 6.
- the aqueous buffer may contain a gentle oxidizing agent.
- the gentle oxidizing agent may be present in a sufficient amount to deglycosylate the tumor cell membrane.
- the gentle oxidizing agent may be present at least about 5 mM to 100 mM, 10 mM to 40 mM, at least about 40 mM to 75 mM, at least about 45 mM to 60 mM, or at least about 50 mM.
- the resuspended tumor cells may be incubated in an aqueous buffer containing a gentle oxidizing agent for a time sufficient to deglycosylate the tumor cell membrane.
- the incubation time may be at least 0.5 to at least 3 hours, about at least 0.5 to 2 hours, or about at least 1 hour.
- the incubation with a gentle oxidizing agent may occur at a temperature that is sufficient to deglycosylate the tumor cell membrane.
- the incubation temperature is between about 15°C to 35°C, 20°C to 32°C, at least 20°C to 30°C, at least 22°C to 25°C, or at least 23°C.
- the incubation may occur in the absence of light.
- the gentle oxidizing agent may be sodium metaperiodate.
- the incubation of resuspended tumor cells in an aqueous buffer containing a gentle oxidizing agent may be terminated.
- oxidation may be terminated by addition of a solution known to end the oxidation process.
- the termination solution is preferably selected from the group, sodium sulfite, sodium bicarbonate, glycerol, or ethylene glycol.
- oxidation may be terminated by addition of ethylene glycol.
- the incubation of resuspended tumor cells in an aqueous buffer containing a gentle oxidizing agent may be terminated by the addition of at least about 25 ⁇ to 75 ⁇ , 45 ⁇ to 55 ⁇ , or 50 ⁇ of ethylene glycol per milliliter of aqueous buffer.
- a method of the present disclosure compromises lysing tumor cells following incubation with one or more deglycosylating agents, wherein after tumor cell lysis, the cellular lysate is stored. It is appreciated that one skilled in the art would be able to select an appropriate method for lysing tumor cells for purposes of the present disclosure.
- a non-limiting example of a method of tumor cell lysis may be that tumor cells undergo one or more freeze-thaw cycles.
- tumor cells may be frozen at least about -70°C to -90°C, at least about - 75°C to -85°C, or at least about -80°C.
- tumor cells may be thawed at least about 20°C to 50°C, at least about 35°C to 40°C, or at least about 37°C. In one embodiment, tumor cells may be subjected to about 2 to 7 freeze-thaw cycles, about 3 to 6 freeze-thaw cycles, about 4 to 5 freeze-thaw cycles, or about 5 freeze-thaw cycles.
- Lysed tumor cells may be immediately stored between about 2°C to 8°C, about 3°C to 5°C, about 4°C to 5, or about 4°C.
- lysed tumor cells may be stored for up to 6 weeks, up to 5 weeks, at least 4 weeks, at least 3 weeks, at least 2 weeks, or up to least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days or greater at a temperature between about 2°C to 8°C.
- lysed tumor cells may be stored up to about 1 to 7 days , at least 2 to 6 days, at least 3 to 5 days, at least 3 to 4 days or greater at least about 2°C to 8°C.
- lysed tumor cells may be immediately stored at least about -50°C to -90°C, at least about -60°C to - 85°C, at least about -75°C to -85, or at least about -80°C. In another embodiment, lysed tumor cells may be stored up to least about 1 month, at least about 6 months, at least about 1 year, at least about 2 years, at least about 3 years, at least about 4 years, at least about 5 years or greater at least about -50°C to -90°C.
- a method of the present disclosure also comprises combining deglycosylated tumor cell lysate with an adjuvant system to form a vaccine.
- an adjuvant system is at least one adjuvant, or at least one immunomodulator, or a combination of adjuvants and immunomodulators.
- adjuvants as used herein are agents that enhance the immune response of an antigen.
- one or more adjuvants may be a particulate adjuvant.
- one or more adjuvants may be an emulsion.
- one or more adjuvants may be a water-in-oil emulsion, oil-in-water emulsion, water-in-oil-in-water emulsion.
- the emulsion can be based in particular on light liquid paraffin oil (European Pharmacopea type); isoprenoid oil such as squalane or squalene oil resulting from the oligomerization of alkenes, in particular of isobutene or decene; esters of acids or of alcohols containing a linear alkyl group, more particularly plant oils, ethyl oleate, propylene glycol di-(caprylate/caprate), glyceryl tri-(caprylate/caprate) or propylene glycol dioleate; esters of branched fatty acids or alcohols, in particular isostearic acid esters.
- the oil is used in combination with emulsifiers to form the emulsion.
- the emulsifiers are preferably nonionic surfactants, in particular esters of sorbitan, of mannide (e.g. anhydromannitol oleate), of glycol, of polyglycerol, of propylene glycol and of oleic, isostearic, ricinoleic or hydroxystearic acid, which are optionally ethoxylated, and polyoxypropylene-polyoxyethylene copolymer blocks, in particular the Pluronic products, especially L121. See Hunter et al, The Theory and Practical Application of Adjuvants (Ed.Stewart-Tull, D. E. S.).
- one or more adjuvants may be a liposome.
- one or more adjuvants may be a microsphere of biodegradable polymers.
- one or more adjuvants may be an immunomodulator.
- an adjuvant system of the present disclosure may be any combination of adjuvants and immunomodulators.
- immunomodulators comprise monophosphoryl lipid A, bark-saponin Quil A, dsRNA analogues, and N-acetyl muramyl-L- alanyl-D-isoglutamine.
- adjuvant systems useful to the present disclosure include, but are not limited to, the RIBI adjuvant system (Ribi Inc.), Block co-polymer (CytRx, Atlanta GA), SAF-M (Chiron, Emeryville CA), AS 15, MF59, Avridine lipid-amine adjuvant, heat-labile enterotoxin from E. coli (recombinant or otherwise), cholera toxin, IMS 1314, GLA-SE, IC31, CAFOl, ISCOMs, or muramyl dipeptide among many others.
- the adjuvant system may be AS01.
- the adjuvant system may be AS02.
- the adjuvant system may be AS03.
- the adjuvant system may be AS04.
- a method of this disclosure comprises combining deglycosylated tumor cell lysates with an adjuvant system to form a vaccine.
- lysates from about at least 0.5 to 100 million or greater, at least 5 to 80 million or greater, at least 10 to 70 million or greater, at least 15 to 65 million or greater, at least 20 to 60 million or greater, at least 30 to 50 million or greater, at least 40 to 50 million or greater, or at least 45 to 50 million or greater deglycosylated tumor cells may be mixed with an adjuvant system.
- vaccines may be immediately stored between about 2°C to
- vaccines may be stored up to least about 1 day, at least about 1 week, at least about 2 weeks, at least about 1 month, at least about 3 months, at least about 6 months, at least about 1 year or more at a temperature between about 2°C to 8°C.
- vaccines may be stored up to least about 1 to about 7 days, at least about 1 to about 2 weeks, at least about 2 weeks to about 1 month, at least about 1 month to about 3 months, at least about 3 months to about 6 months, at least about 6 months to about 1 year or more at a temperature of about 2°C to 8°C.
- One embodiment of the present disclosure provides methods of administering an adjuvanted, deglycosylated autologous tumor composition to a patient for treatment of cancer.
- the method comprises one or more inoculations over an appropriate range of time wherein at least about 5% or greater of tumor growth may be impaired compared to tumor growth in an untreated patient with identical disease condition and predicted outcome.
- the delivery route may be selected to produce the appropriate immune response.
- the delivery route may be subcutaneous.
- the delivery route may be intradermal.
- the delivery route may be transdermal.
- the delivery route may be intramuscular.
- the delivery route may be intralymphatic. It is appreciated that one skilled in the art would be able to select an appropriate route for vaccine delivery for purposes of the present disclosure.
- one dose of adjuvanted, deglycosylated autologous tumor vaccine may be at least about 0.05 ml or greater to at least about 1.0 ml or greater, at least about 0.2 ml or greater to at least about 0.8 ml or greater, at least about 0.4 ml or greater to at least about 0.6 ml or greater.
- one dose of adjuvanted, deglycosylated autologous tumor vaccine may be at least about 0.05 ml or greater, at least about 0.1 ml or greater, at least about 0.2 ml or greater, at least about 0.3 ml or greater, at least about 0.4 ml or greater, at least about 0.5 ml or greater, at least about 0.6 ml or greater, at least about 0.7 ml or greater, at least about 0.8 ml or greater, at least about 0.9 ml or greater, at least about 1.0 ml or greater.
- one dose of adjuvanted, deglycosylated autologous tumor vaccine may be at least about 0.05 ml or greater to at least about 0.1 ml or greater, at least about 0.1 ml or greater to at least about 0.2 ml or greater, at least about 0.2 ml or greater to at least about 0.3 ml or greater, at least about 0.3 ml or greater to at least about 0.4 ml or greater, at least about 0.4 ml or greater to at least about 0.5 ml or greater, at least about 0.5 ml or greater to at least about 0.6 ml or greater, at least about 0.6 ml or greater to at least about 0.7 ml or greater, at least about 0.7 ml or greater to at least about 0.8 ml or greater, at least about 0.8 ml or greater to at least about 0.9 ml or greater, at least about 0.9 ml or greater to at least about 1.0 ml or greater.
- one dose of adjuvanted, deglycosylated autologous tumor vaccine may contain lysate in amounts as described above, or from at least about 5 to 60 million or more, about at least about 20 to 50 million or more, about at least about 40 to 50 million or more, or about at least about 45 to 50 million or more deglycosylated tumor cells.
- one dose of tumor vaccine may contain lysate from an amount of deglycosylated tumor cells as described above, or at least about 5 million or more, at least about 10 million or more, at least about 15 million or more, at least about 20 million or more, at least about 25 million or more, at least about 30 million or more, at least about 35 million or more, at least about 40 million or more, at least about 45 million or more, at least about 50 million or more, at least about 55 million or more, at least about 60 million or more deglycosylated tumor cells.
- one dose of tumor vaccine may contain lysate from an amount of tumor cells as described above, or at least about 5 million or more to least about 10 million or more, at least about 10 million or more to least about 10 million or more, at least about 15 million or more to least about 20 million or more, at least about 20 million or more to least about 25 million or more, at least about 25 million or more to at least about 30 million or more, at least about 30 million or more to at least about 35 million or more, at least about 35 million or more to at least about 40 million or more, at least about 40 million or more to at least about 45 million or more, at least about 45 million or more to at least about 50 million or more, at least about 50 million or more to at least about 55 million or more, at least about 55 million or more to at least about 60 million or more deglycosylated tumor cells.
- a patient may be inoculated with a dose of the adjuvanted, deglycosylated autologous tumor vaccine once or multiple times.
- inoculation of the patient with a dose of the tumor vaccine may occur multiple times until desired results are observed. It is appreciated that one skilled in the art would be able to select an appropriate number of inoculations to achieve the desired response for purposes of the present disclosure.
- inoculation of the patient with a dose of the adjuvanted, deglycosylated autologous tumor vaccine may occur once, up to two times, up to three times, up to four times, or up to five times.
- One preferred dose regimen comprises four inoculations.
- a patient may be inoculated with a dose of the adjuvanted, deglycosylated autologous tumor vaccine multiple times at irregular intervals.
- a patient may be inoculated with a dose of the tumor vaccine multiple times at regular intervals.
- a patient may be inoculated with a dose of the tumor vaccine multiple times at about at least 1-week or greater, at least 2-week or greater, at least 3 -week or greater, at least 4-week or greater, at least 5 -week or greater, at least 6- week or greater intervals.
- a patient may be inoculated with a dose of the tumor vaccine multiple times at about at least 1-week or greater, at least 2-week or greater to at least 3 -week or greater, at least 3 -week or greater to at least 4-week or greater, at least 4-week or greater to at least 5 -week or greater, at least 5 -week or greater to at least 6-week or greater intervals. It is appreciated that one skilled in the art would be able to select an appropriate interval of inoculation regimen to achieve the desired response for purposes of the present disclosure.
- one or more doses of the adjuvanted, deglycosylated autologous tumor vaccine may be administered as a booster vaccine following initial treatment regimen.
- one or more doses of the tumor vaccine may be administered for the lifetime of the patient.
- a dose of the tumor vaccine may be administered as a booster vaccine at least every 3 months or more, at least every 6 months or more, at least every year or more, at least every 2 years or more, at least every 3 years or more following initial treatment regimen. It is appreciated that one skilled in the art would be able to select an appropriate interval of booster inoculation regimen to achieve the desired response for purposes of the present disclosure.
- Another embodiment of the present disclosure may be to combine the adjuvanted, deglycosylated autologous tumor vaccine and treatment prepared as described above with one or more additional therapies that are appropriate for cancer treatment.
- the adjuvanted, deglycosylated autologous tumor vaccine, containing complete tumor cell lysate may be combined with another vaccine containing one or more tumor antigens.
- the adjuvanted, deglycosylated autologous tumor vaccine, containing complete tumor cell lysate may be combined with another vaccine containing one or more tumor growth factor receptors.
- implementation of an adjuvanted, deglycosylated autologous tumor vaccine and treatment may be combined with standard-of-care cancer therapies.
- standard-of-care cancer therapies entail tone or more treatments accepted by medical experts as a proper treatment for a certain type of disease and that is widely used by healthcare professionals. These standard of care cancer therapies include chemotherapy as well as radiation therapy. It is appreciated that one skilled in the art would be able to select one or more appropriate standard-of-care cancer therapies to use in combination with the tumor vaccine described in the present disclosure for the desired outcome.
- the method of the present disclosure comprises one or more inoculations over an appropriate range of time wherein tumor growth may be impaired compared to tumor growth in an untreated patient with identical disease condition and predicted outcome.
- tumor growth may be stopped following treatment with the tumor vaccine described herein.
- tumor growth may be impaired at least about 5% or greater to at least about 100%, at least about 10% or greater to at least about 95% or greater, at least about 20% or greater to at least about 80% or greater, at least about 40% or greater to at least about 60% or greater compared to an untreated patient with identical disease condition and predicted outcome.
- tumors in patients treated using the methods and compositions of the disclosure have tumors that grow at least 5% less (or more as described above) when compared to an untreated patient with identical disease condition and predicted outcome.
- tumor growth may be impaired at least about 5% or greater, at least about 10% or greater, at least about 15% or greater, at least about 20% or greater, at least about 25% or greater, at least about 30% or greater, at least about 35% or greater, at least about 40% or greater, at least about 45%) or greater, at least about 50% or greater, at least about 55% or greater, at least about 60% or greater, at least about 65% or greater, at least about 70% or greater, at least about 75% or greater, at least about 80% or greater, at least about 85% or greater, at least about 90% or greater, at least about 95% or greater, at least about 100% compared to an untreated patient with identical disease condition and predicted outcome.
- tumor growth may be impaired at least about 5% or greater to at least about 10% or greater, at least about 10% or greater to at least about 15% or greater, at least about 15% or greater to at least about 20% or greater, at least about 20% or greater to at least about 25% or greater, at least about 25% or greater to at least about 30% or greater, at least about 30% or greater to at least about 35% or greater, at least about 35% or greater to at least about 40% or greater, at least about 40% or greater to at least about 45% or greater, at least about 45% or greater to at least about 50% or greater, at least about 50% or greater to at least about 55% or greater, at least about 55% or greater, at least about 55% or greater to at least about 60% or greater, at least about 60% or greater to at least about 65% or greater, at least about 65% or greater to at least about 70% or greater, at least about 70% or greater to at least about 75% or greater, at least about 75% or greater to at least about 80% or greater, at least about 80% or greater to at least about 85% or greater, at least about
- treatment of tumors results in a shrinking of a tumor in comparison to the starting size of the tumor.
- This shrinking is at least about 5% or greater to at least about 10% or greater, at least about 10% or greater to at least about 15% or greater, at least about 15% or greater to at least about 20% or greater, at least about 20% or greater to at least about 25% or greater, at least about 25% or greater to at least about 30% or greater, at least about 30% or greater to at least about 35% or greater, at least about 35% or greater to at least about 40% or greater, at least about 40% or greater to at least about 45% or greater, at least about 45% or greater to at least about 50% or greater, at least about 50%) or greater to at least about 55% or greater, at least about 55% or greater to at least about 60%) or greater, at least about 60% or greater to at least about 65% or greater, at least about 65%) or greater to at least about 70% or greater, at least about 70% or greater to at least about 75%) or greater, at least about 75% or greater to at least about 80% or
- the method of the present disclosure comprises one or more inoculations over an appropriate range of time wherein the presence of tumor markers is lower compared to the presence of tumor markers in an untreated patient with identical disease condition and predicted outcome.
- tumor markers are defined as substances produced by cancer or by other cells of the body in response to cancerous conditions.
- Non-limiting examples of tumor markers include alpha-fetoprotein, beta-2-microglobulin, beta-human chorionic gonadotropin, BCR-ABL fusion gene, CA19-9, CD20, HE4, lactate dehydrogenase, prostate-specific antigen, and various others.
- the presence of tumor markers may be ablated following treatment with the tumor vaccine described herein.
- the presence of tumor markers may be decreased at least about 5% or greater to at least about 100%, at least about 10% or greater to at least about 95% or greater, at least about 20%) or greater to at least about 80%> or greater, at least about 40% or greater to at least about 60%) or greater compared to an untreated patient with identical disease condition and predicted outcome.
- the presence of tumor markers may be decreased at least about 5%) or greater, at least about 10%> or greater, at least about 15%> or greater, at least about 20% or greater, at least about 25% or greater, at least about 30% or greater, at least about 35% or greater, at least about 40% or greater, at least about 45% or greater, at least about 50% or greater, at least about 55% or greater, at least about 60% or greater, at least about 65% or greater, at least about 70% or greater, at least about 75% or greater, at least about 80% or greater, at least about 85% or greater, at least about 90% or greater, at least about 95% or greater, at least about 100% compared to an untreated patient with identical disease condition and predicted outcome.
- the presence of tumor markers may be decreased at least about 5% or greater to at least about 10% or greater, at least about 10% or greater to at least about 15% or greater, at least about 15% or greater to at least about 20% or greater, at least about 20% or greater to at least about 25% or greater, at least about 25% or greater to at least about 30% or greater, at least about 30% or greater to at least about 35% or greater, at least about 35% or greater to at least about 40% or greater, at least about 40% or greater to at least about 45% or greater, at least about 45% or greater to at least about 50% or greater, at least about 50% or greater to at least about 55% or greater, at least about 55% or greater, at least about 55% or greater, at least about 55% or greater, at least about 60% or greater, at least about 60% or greater to at least about 65% or greater, at least about 65% or greater to at least about 70% or greater, at least about 70% or greater to at least about 75% or greater, at least about 75% or greater to at least about 80% or greater, at least about 80% or greater to
- the method of the present disclosure comprises one or more inoculations over an appropriate range of time wherein the cancer life expectancy may be improved compared to the cancer life expectancy of an untreated patient with identical disease condition and predicted outcome.
- cancer life expectancy is defined as the time at which 50 percent of patients are alive and 50 percent have passed away.
- cancer life expectancy may be indefinite following treatment with the tumor vaccine described herein.
- cancer life expectancy may be increased at least about 5%) or greater to at least about 100%, at least about 10% or greater to at least about 95% or greater, at least about 20% or greater to at least about 80% or greater, at least about 40% or greater to at least about 60% or greater compared to an untreated patient with identical disease condition and predicted outcome.
- cancer life expectancy may be increased at least about 5% or greater, at least about 10% or greater, at least about 15% or greater, at least about 20% or greater, at least about 25% or greater, at least about 30% or greater, at least about 35% or greater, at least about 40% or greater, at least about 45% or greater, at least about 50% or greater, at least about 55% or greater, at least about 60% or greater, at least about 65% or greater, at least about 70% or greater, at least about 75% or greater, at least about 80% or greater, at least about 85% or greater, at least about 90% or greater, at least about 95% or greater, at least about 100% compared to an untreated patient with identical disease condition and predicted outcome.
- cancer life expectancy may be increased at least about 5% or greater to at least about 10% or greater, at least about 10% or greater to at least about 15% or greater, at least about 15% or greater to at least about 20% or greater, at least about 20% or greater to at least about 25% or greater, at least about 25% or greater to at least about 30% or greater, at least about 30% or greater to at least about 35% or greater, at least about 35% or greater to at least about 40% or greater, at least about 40%) or greater to at least about 45% or greater, at least about 45% or greater to at least about 50%) or greater, at least about 50% or greater to at least about 55% or greater, at least about 55%) or greater to at least about 60% or greater, at least about 60% or greater to at least about 65%) or greater, at least about 65% or greater to at least about 70% or greater, at least about 70% or greater to at least about 75% or greater, at least about 75% or greater to at least about 80%) or greater, at least about 80%> or greater to at least about 85%> or greater
- the vaccine may be derived from a cancerous lesion harvested from a patient.
- the cancer may be a primary cancer, a metastases, or primary cancer and metastases.
- the cancer may be a solid cancer.
- the cancer may be a liquid cancer.
- the tumor grade of the harvested tissue may be between 1 and 4, may be 1, may be 2, may be 3, or may be 4.
- methods of harvesting tumors from patients are known in the art and it is appreciated that one skilled in the art would be able to select one or more appropriate methods to harvest cancerous tissue or cells as described in the present disclosure.
- a harvested tumor cell source to generate the tumor vaccine is large enough to obtain a sample from which the composition can be made.
- the tumor cell source may be between about 0.2 cm 3 to at least about 20 cm 3 or greater, at least 2 cm 3 to at least about 18 cm 3 or greater, at least 3 cm3 to at least about 15 cm 3 or greater, at least 4 cm 3 to at least about 12 cm 3 or greater, at least 5 cm 3 to at least about 10 cm 3 or greater, or at least 6 cm 3 to at least about 8 cm 3 or greater.
- a harvested tumor cell source may be at least about 1 cm 3 or greater, at least about 2 cm 3 or greater, at least about 3 cm 3 or greater, at least about 4 cm 3 or greater, at least about 5 cm 3 or greater, at least about 6 cm 3 or greater, at least about 7 cm 3 or greater, at least about 8 cm 3 or greater, at least about 9 cm 3 or greater, at least about 10 cm 3 or greater, at least about 1 1 cm 3 or greater, at least about 12 cm 3 or greater, at least about 13 cm 3 or greater, at least about 14 cm 3 or greater, at least about 15 cm 3 or greater, at least about 16 cm 3 or greater, at least about 17 cm 3 or greater, at least about 18 cm 3 or greater, at least about 19 cm 3 or greater, or at least about 20 cm 3 or greater.
- a harvested tumor cell source may be at least about 0.2 cm 3 to about 0.3 cm 3 or greater, at least about 0.3 cm 3 to about 0.4 cm 3 or greater, at least about 0.4 cm 3 to about 0.5 cm 3 or greater, at least about 0.5 cm 3 to about 1 cm 3 or greater, at least about 1 cm 3 to about 2 cm 3 or greater, at least about 2 cm 3 to about 3 cm 3 or greater, at least about 3 cm 3 to about 4 cm 3 or greater, at least about 4 cm 3 to about 5 cm 3 or greater, at least about 5 cm 3 to about 6 cm 3 or greater, at least about 6 cm 3 to about 7 cm 3 or greater, at least about 7 cm 3 to about 8 cm 3 or greater, at least about 8 cm 3 to about 9 cm 3 or greater, at least about 9 cm 3 to about 10 cm 3 or greater, at least about 10 cm 3 to about 11 cm 3 or greater, at least about 11 cm 3 to about 12 cm 3 or greater, at least about 12 cm 3 to about 13 cm 3 or greater, at least about 13 cm 3 to about 14 cm 3
- a harvested tumor cell source may yield a number of cells as described above or between at least about 0.5 million cells to at least about 100 million cells or greater, at least about 3 million cells to at least about 60 million cells or greater, at least about 5 million cells to at least about 60 million cells or greater, at least about 10 million cells to at least about 60 million cells or greater, at least about 15 million cells to at least about 60 million cells or greater, at least about 20 million cells to at least about 60 million cells or greater, at least about 25 million cells to at least about 50 million cells or greater, at least about 30 million cells to at least about 40 million cells or greater, or at least about 45 million cells to at least about 45 million cells or greater.
- tumor cells may be expanded in culture to obtain at least about 0.5 million cells, at least about 1 million cells, at least about 5 million cells, at least about 7 million cells, at least about 10 million cells, at least about 15 million cells, at least about 20 million cells, at least about 25 million cells, at least about 30 million cells, 35 million cells, at least about 40 million cells, at least about 45 million cells, at least about 50 million cells, at least about 55 million cells, at least about 60 million cells, or greater.
- tumor cells may be expanded in culture to obtain at least about 0.5 million cells to at least about 60 million cells, at least about 5 million cells to at least about 60 million cells, at least about 7 million cells to at least about 60 million cells, at least about 10 million cells to at least about 15 million cells, at least about 15 million cells to at least about 20 million cells, at least about 20 million cells to at least about 25 million cells, at least about 25 million cells to at least about 30 million cells, at least about 30 million cells to at least about 35 million cells, 35 million cells to at least about 40 million cells, at least about 40 million cells to at least about 45 million cells, at least about 45 million cells to at least about 50 million cells, at least about 50 million cells to at least about 55 million cells, at least about 55 million cells to at least about 60 million cells.
- An adjuvanted, deglycosylated autologous tumor vaccine and treatment may be composed of tumor cells wherein a majority of tumor cell membrane may be deglycosylated.
- at least about 55% or more of the tumor cell membrane may be deglycosylated.
- at least about 65% or more of the tumor cell membrane may be deglycosylated.
- at least about 75% or more of the tumor cell membrane may be deglycosylated.
- at least about 85% or more of the tumor cell membrane may be deglycosylated.
- at least about 95% or more of the tumor cell membrane may be deglycosylated.
- At least about 55% to 95% or greater, at least about 65% to 95% or greater, at least about 75% to 95% or greater, at least about 85% to 95% or greater, or at least about 90% to 95% or greater of tumor cell membrane may be deglycosylated.
- An adjuvanted, deglycosylated autologous tumor vaccine and treatment may be composed of deglycosylated tumor cell lysate that may be stored for vaccine production. It is appreciated that one skilled in the art would be able to select an appropriate method for lysing tumor cells and for storing tumor cells for purposes of the present disclosure. Lysed tumor cells may be immediately stored as described above or at least about 2°C to 8°C, at least about 3°C to 5°C, at least about 4°C to 5, or at least about 4°C.
- vaccines may be stored up to least about 1 day, at least about 1 week, at least about 2 weeks, at least about 1 month, at least about 3 months, at least about 6 months, at least about 1 year or more at a temperature between about 2°C to 8°C.
- vaccines may be stored up to least about 1 to about 7 days, at least about 1 to about 2 weeks, at least about 2 weeks to about 1 month, at least about 1 month to about 3 months, at least about 3 months to about 6 months, at least about 6 months to about 1 year or more at a temperature of about 2°C to 8°C.
- lysed tumor cells may be immediately stored at least about -50°C to -90°C, at least about -60°C to -85°C, at least about -75°C to -85, or at least about -80°C. In another embodiment, lysed tumor cells may be stored up to least about 1 month, at least about 6 months, at least about 1 year, at least about 2 years, at least about 3 years, at least about 4 years, at least about 5 years or greater at least about -50°C to -90°C.
- An adjuvanted, deglycosylated autologous tumor vaccine and treatment may be composed of deglycosylated tumor cell lysate combined with an adjuvant system.
- Suitable adjuvant systems useful to the present disclosure are known in the art and are described above.
- the adjuvant system may be AS01, AS02, and/or AS03.
- the adjuvant system may be AS04.
- an adjuvanted, deglycosylated autologous tumor vaccine may be immediately stored as described above or at least about 2°C to 8°C, at least about 3°C to 5°C, at least about 4°C to 5, or at least about 4°C.
- vaccines may be stored up to least about 1 day, at least about 1 week, at least about 2 weeks, at least about 1 month, at least about 3 months, at least about 6 months, at least about 1 year or more at a temperature between about 2°C to 8°C.
- vaccines may be stored up to least about 1 to about 7 days, at least about 1 to about 2 weeks, at least about 2 weeks to about 1 month, at least about 1 month to about 3 months, at least about 3 months to about 6 months, at least about 6 months to about 1 year or more at a temperature of about 2°C to 8°C.
- the delivery route may be selected to produce the appropriate immune response.
- the delivery route may be subcutaneous.
- the delivery route may be intradermal.
- the delivery route may be transdermal.
- the delivery route may be intramuscular.
- the delivery route may be intralymphatic. It is appreciated that one skilled in the art would be able to select an appropriate route for vaccine delivery for purposes of the present disclosure.
- One dose of an adjuvanted, deglycosylated autologous tumor vaccine and treatment may be composed of a volume as described above or of at least about 0.05 ml or greater to at least about 1.0 ml or greater, at least about 0.2 ml or greater to at least about 0.8 ml or greater, at least about 0.4 ml or greater to at least about 0.6 ml or greater.
- one dose of adjuvanted, deglycosylated autologous tumor vaccine may be at least about 0.05 ml or greater, at least about 0.1 ml or greater, at least about 0.2 ml or greater, at least about 0.3 ml or greater, at least about 0.4 ml or greater, at least about 0.5 ml or greater, at least about 0.6 ml or greater, at least about 0.7 ml or greater, at least about 0.8 ml or greater, at least about 0.9 ml or greater, at least about 1.0 ml or greater.
- one dose of adjuvanted, deglycosylated autologous tumor vaccine may be at least about 0.05 ml or greater to at least about 0.1 ml or greater, at least about 0.1 ml or greater to at least about 0.2 ml or greater, at least about 0.2 ml or greater to at least about 0.3 ml or greater, at least about 0.3 ml or greater to at least about 0.4 ml or greater, at least about 0.4 ml or greater to at least about 0.5 ml or greater, at least about 0.5 ml or greater to at least about 0.6 ml or greater, at least about 0.6 ml or greater to at least about 0.7 ml or greater, at least about 0.7 ml or greater to at least about 0.8 ml or greater, at least about 0.8 ml or greater to at least about 0.9 ml or greater, at least about 0.9 ml or greater to at least about 1.0 ml or greater.
- One dose of an adjuvanted, deglycosylated autologous tumor vaccine and treatment may be composed of lysate as described above, or from at least about 0.5 to 60 million or more, about at least about 20 to 50 million or more, about at least about 40 to 50 million or more, or about at least about 45 to 50 million or more deglycosylated tumor cells.
- one dose of tumor vaccine may contain lysate from at least about 0.5 million or more, at least about 1 million or more, at least about 5 million or more, at least about 10 million or more, at least about 15 million or more, at least about 20 million or more, at least about 25 million or more, at least about 30 million or more, at least about 35 million or more, at least about 40 million or more, at least about 45 million or more, at least about 50 million or more, at least about 55 million or more, at least about 60 million or more deglycosylated tumor cells.
- one dose of tumor vaccine may contain lysate from at least about 0.5 million or more to least about 1 million or more, at least about 1 million or more to least about 5 million or more, at least about 5 million or more to least about 10 million or more, at least about 10 million or more to least about 15 million or more, at least about 15 million or more to least about 20 million or more, at least about 20 million or more to least about 25 million or more, at least about 25 million or more to at least about 30 million or more, at least about 30 million or more to at least about 35 million or more, at least about 35 million or more to at least about 40 million or more, at least about 40 million or more to at least about 45 million or more, at least about 45 million or more to at least about 50 million or more, at least about 50 million or more to at least about 55 million or more, at least about 55 million or more to at least about 60 million or more deglycosylated tumor cells.
- a treatment regimen composed of an adjuvanted, deglycosylated autologous tumor vaccine and treatment may include inoculation of the patient once or multiple times.
- inoculation of the patient with a dose of the tumor vaccine may occur multiple times until desired results are observed. It is appreciated that one skilled in the art would be able to select an appropriate number of inoculations to achieve the desired response for purposes of the present disclosure.
- inoculation of the patient with a dose of the adjuvanted, deglycosylated autologous tumor vaccine may occur once, up to two times, up to three times, up to four times, up to five times.
- a patient may be inoculated with a dose of the adjuvanted, deglycosylated autologous tumor vaccine multiple times at irregular intervals.
- a patient may be inoculated with a dose of the tumor vaccine multiple times at regular intervals.
- a patient may be inoculated with a dose of the tumor vaccine multiple times at about at least 2-week or greater, at least 3 -week or greater, at least 4-week or greater, at least 5 -week or greater, at least 6-week or greater intervals.
- a patient may be inoculated with a dose of the tumor vaccine multiple times at about at least 2-week or greater to at least 3 -week or greater, at least 3- week or greater to at least 4-week or greater, at least 4-week or greater to at least 5 -week or greater, at least 5-week or greater to at least 6-week or greater intervals. It is appreciated that one skilled in the art would be able to select an appropriate interval of inoculation regimen to achieve the desired response for purposes of the present disclosure.
- a booster vaccine composed of an adjuvanted, deglycosylated autologous tumor vaccine may be administered following initial treatment regimen.
- one or more doses of the tumor vaccine may be administered for the lifetime of the patient.
- a dose of the tumor vaccine may be administered as a booster vaccine at least every 3 months or more, at least every 6 months or more, at least every year or more, at least every 2 years or more, at least every 3 years or more following initial treatment regimen. It is appreciated that one skilled in the art would be able to select an appropriate interval of booster inoculation regimen to achieve the desired response for purposes of the present disclosure.
- an adjuvanted, deglycosylated autologous tumor vaccine and treatment may impair growth of cancerous tumors in an inoculated patient compared to an untreated patient with identical disease condition and predicted outcome.
- tumor growth may be stopped following treatment with the tumor vaccine described herein.
- tumor growth may be impaired at least about 5% or greater to at least about 100%, at least about 10% or greater to at least about 95% or greater, at least about 20% or greater to at least about 80% or greater, at least about 40% or greater to at least about 60% or greater compared to an untreated patient with identical disease condition and predicted outcome.
- tumor growth refers to a decrease in growth of a tumor in comparison to tumor growth in an untreated patient with identical disease condition and predicted outcome.
- tumor growth may be impaired, at least about 5% or greater, at least about 10% or greater, at least about 15% or greater, at least about 20% or greater, at least about 25% or greater, at least about 30% or greater, at least about 35% or greater, at least about 40% or greater, at least about 45% or greater, at least about 50% or greater, at least about 55% or greater, at least about 60% or greater, at least about 65% or greater, at least about 70% or greater, at least about 75% or greater, at least about 80% or greater, at least about 85% or greater, at least about 90% or greater, at least about 95% or greater, at least about 100% compared to an untreated patient with identical disease condition and predicted outcome.
- tumor growth may be impaired at least about 5% or greater to at least about 10%) or greater, at least about 10% or greater to at least about 15% or greater, at least about 15%) or greater to at least about 20% or greater, at least about 20% or greater to at least about 25%) or greater, at least about 25% or greater to at least about 30% or greater, at least about 30% or greater to at least about 35% or greater, at least about 35% or greater to at least about 40%) or greater, at least about 40% or greater to at least about 45% or greater, at least about 45% or greater to at least about 50% or greater, at least about 50% or greater to at least about 55%) or greater, at least about 55% or greater to at least about 60% or greater, at least about 60% or greater to at least about 65% or greater, at least about 65% or greater to at least about 70% or greater, at least about 70% or greater to at least about 75% or greater, at least about 75% or greater to at least about 80% or greater, at least about 80% or greater to at least about 85% or greater, at least about
- treatment of tumors results in a shrinking of a tumor in comparison to the starting size of the tumor.
- This shrinking is at least about 5% or greater to at least about 10% or greater, at least about 10% or greater to at least about 15% or greater, at least about 15% or greater to at least about 20% or greater, at least about 20% or greater to at least about 25% or greater, at least about 25% or greater to at least about 30% or greater, at least about 30% or greater to at least about 35% or greater, at least about 35% or greater to at least about 40% or greater, at least about 40%) or greater to at least about 45% or greater, at least about 45% or greater to at least about 50%) or greater, at least about 50% or greater to at least about 55% or greater, at least about 55%) or greater to at least about 60% or greater, at least about 60% or greater to at least about 65%) or greater, at least about 65% or greater to at least about 70% or greater, at least about 70%) or greater to at least about 75% or greater, at least about 75% or greater to at least about 80%
- an adjuvanted, deglycosylated autologous tumor vaccine and treatment may reduce the presence of one or more tumor markers in an inoculated patient compared to an untreated patient with identical disease condition and predicted outcome.
- the presence of tumor markers may be ablated following treatment with the tumor vaccine described herein.
- the presence of tumor markers may be decreased as described above or at least about 5% or greater to at least about 100%, at least about 10% or greater to at least about 95% or greater, at least about 20% or greater to at least about 80%> or greater, at least about 40% or greater to at least about 60%) or greater compared to an untreated patient with identical disease condition and predicted outcome.
- the presence of tumor markers may be decreased at least about 5% or greater, at least about 10%> or greater, at least about 15%> or greater, at least about 20%) or greater, at least about 25% or greater, at least about 30%> or greater, at least about 35%) or greater, at least about 40% or greater, at least about 45% or greater, at least about 50% or greater, at least about 55% or greater, at least about 60% or greater, at least about 65% or greater, at least about 70% or greater, at least about 75% or greater, at least about 80% or greater, at least about 85% or greater, at least about 90% or greater, at least about 95% or greater, at least about 100% compared to an untreated patient with identical disease condition and predicted outcome.
- the presence of tumor markers may be decreased at least about 5% or greater to at least about 10% or greater, at least about 10% or greater to at least about 15% or greater, at least about 15% or greater to at least about 20% or greater, at least about 20% or greater to at least about 25% or greater, at least about 25% or greater to at least about 30% or greater, at least about 30% or greater to at least about 35% or greater, at least about 35% or greater to at least about 40% or greater, at least about 40% or greater to at least about 45% or greater, at least about 45% or greater to at least about 50% or greater, at least about 50% or greater to at least about 55% or greater, at least about 55% or greater, at least about 55% or greater, at least about 55% or greater, at least about 60% or greater, at least about 60% or greater to at least about 65% or greater, at least about 65% or greater to at least about 70% or greater, at least about 70% or greater to at least about 75% or greater, at least about 75% or greater to at least about 80% or greater, at least about 80% or greater to
- an adjuvanted, deglycosylated autologous tumor vaccine and treatment may improve the cancer life expectancy of an inoculated patient compared to that of an untreated patient with identical disease condition and predicted outcome.
- cancer life expectancy may be indefinite following treatment with the tumor vaccine described herein.
- cancer life expectancy may be increased as described above or at least about 5% or greater to at least about 100%, at least about 10%> or greater to at least about 95% or greater, at least about 20% or greater to at least about 80%> or greater, at least about 40% or greater to at least about 60%> or greater compared to an untreated patient with identical disease condition and predicted outcome.
- cancer life expectancy may be increased at least about 5% or greater, at least about 10% or greater, at least about 15% or greater, at least about 20% or greater, at least about 25%) or greater, at least about 30% or greater, at least about 35% or greater, at least about 40%) or greater, at least about 45% or greater, at least about 50% or greater, at least about 55% or greater, at least about 60% or greater, at least about 65% or greater, at least about 70% or greater, at least about 75% or greater, at least about 80% or greater, at least about 85% or greater, at least about 90% or greater, at least about 95% or greater, at least about 100% compared to an untreated patient with identical disease condition and predicted outcome.
- cancer life expectancy may be increased at least about 5% or greater to at least about 10% or greater, at least about 10% or greater to at least about 15% or greater, at least about 15% or greater to at least about 20% or greater, at least about 20% or greater to at least about 25% or greater, at least about 25% or greater to at least about 30% or greater, at least about 30% or greater to at least about 35% or greater, at least about 35% or greater to at least about 40% or greater, at least about 40% or greater to at least about 45% or greater, at least about 45%) or greater to at least about 50% or greater, at least about 50% or greater to at least about 55%) or greater, at least about 55% or greater to at least about 60% or greater, at least about 60%) or greater to at least about 65% or greater, at least about 65% or greater to at least about 70%) or greater, at least about 70% or greater to at least about 75% or greater, at least about 75%) or greater to at least about 80% or greater, at least about 80% or greater to at least about 85%) or greater, at least about 80%
- the composition of the present disclosure can comprise a deglycosylated autologous tumor cells or tumor cell lysate as described above, wherein the tumor cells or tumor cell lysate is combined with at least one additional component selected from the group consisting of pharmaceutically-acceptable carriers, adjuvants, diluents, preservatives, antibiotics, and combinations thereof prior to administration.
- pharmaceutically-acceptable carrier refers to includes any and all solvents, dispersion media, coatings, stabilizing agents, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, adsorption delaying agents, and the like.
- Diluents can include water, saline, dextrose, ethanol, glycerol, and the like.
- Isotonic agents can include sodium chloride, dextrose, mannitol, sorbitol, and lactose, among others.
- Stabilizers include albumin and alkali salts of ethylendiamintetracetic acid, among others.
- Adjuvants are as described above.
- a "protectant” or “preservative” as used herein refers to an anti-microbiological active agent, such as for example Neomycin, Amphoteracin B, Gentamycin, Merthiolate, and the like. Of these, Neomycin and/or Amphoteracin B are particularly preferred. In particular adding a protectant is most preferred for the preparation of a multi-dose composition. Those anti- microbiological active agents are added in concentrations effective to prevent the composition of interest from any microbiological contamination or for inhibition of any microbiological growth within the composition of interest.
- this method can also comprise the addition of any stabilizing agent, such as for example saccharides, trehalose, mannitol, saccharose and the like, to increase and/or maintain product shelf-life.
- any stabilizing agent such as for example saccharides, trehalose, mannitol, saccharose and the like, to increase and/or maintain product shelf-life.
- composition of the present disclosure can comprise a deglycosylated tumor cell lysate, together with a dispersion media, or a solvent, or a coating, or a stabilizing agent, or a diluent, or a preservative, or an adjuvant, or an antibacterial or antifungal agent, or an isotonic agent, or an adsorption delaying agent, or any combination of the above.
- the composition of the present disclosure can comprise deglycosylated autologous tumor cells or deglycosylated tumor cell lysate derived from allogeneic cancer cells.
- allogeneic cancer cells may be sourced from another member of the same species as the patient.
- allogeneic cancer cells may be sourced from another the same tumor type.
- Non-limiting sources of allogeneic cancer cells comprise of laboratory-grown cancer cell lines and tumor cells isolated from a donor.
- allogeneic tumor cells may be genetically modified.
- the composition of the present disclosure may comprise a deglycosylated tumor vaccine derived from deglycosylated allogeneic cancer cells to be used as a cancer prevention vaccine.
- a "cancer prevention vaccine” is administered to healthy patients to prevent cancers from developing.
- the deglycosylated cancer cell cancer prevention vaccine may be derived of cancer cells from multiple cancer types.
- the deglycosylated cancer cell cancer prevention vaccine may be derived of cancer cells from one or more cancer types.
- the deglycosylated cancer cell cancer prevention vaccine may be derived of cancer cells from at least five, at least four, at least three, at least two, at least one cancer types.
- the deglycosylated cancer cell cancer prevention vaccine may be administered to the patient multiple times over an appropriate time span to achieve the desired response. In certain embodiments, the deglycosylated cancer cell cancer prevention vaccine may be administered to the patient at least 10 times, at least 9 times, at least 8 times, at least 7 times, at least 6 times, at least 5 times, at least 4 times, at least 3 times, at least 2 times, at least once. In another embodiment, the deglycosylated cancer cell cancer prevention vaccine may be administered to the patient at appropriate time intervals.
- the deglycosylated cancer cell cancer prevention vaccine may be administered to the patient at least every 5 years, at least every 3 years, at least every year, at least every 9 months, at least every 6 months, at least every 3 months, at least every month, at least every 3 weeks, at least every 2 weeks, at least every week, at least every four days, at least every two days, at least every day.
- FIG. 1 is an x-ray showing metastatic nodule identified throughout the lung fields.
- FIG. 2 is an x-ray showing the metastatic nodules identified in FIG. 1 had progressed.
- FIG. 3 is an x-ray showing no metastatic disease clearly visible after treatment.
- the disclosure teaches a novel therapeutic vaccine approach that can trigger a therapeutic antitumor response in a cancer patient or a healthy subject.
- the inventive approach is to selectively eliminate the carbohydrate sequences from tumor cells without affecting the tumor associated protein epitopes.
- the disclosure further teaches that the evidence that in humans, the expression of Lewis y , SLEX and other carbohydrate sequences increases dramatically on tumor cells near the end stage of cancer, suggests that these TACAs help to make them invulnerable to the immune response. Thus the loss of these TACAs will de-shield these tumor cells from companion dogs, revealing immunogenic molecules that will trigger a therapeutic antitumor response.
- a suitable method may have to be generated to isolate tumor cells from other normal cells within the tumor.
- This type of isolation will likely be specific for the type of cancer cells that are targets.
- Once such tumor cells are isolated it may be important first to shut down protein synthesis with an active DNA crosslinking agent like mitomycin C.
- An active inhibitor of glycosylation may also be necessary to globally eliminate the additional of any more glycan sequences.
- the famous AIDS drug AZT is an excellent inhibitor of glycosylation at a final concentration of about 20 ⁇ .
- These two drugs can be given to the tumor cells, which may be incubated with a variety of different glycosidases (neuraminidase, ⁇ -galactosidase, ( ⁇ -and oc-N- acetylgalactosaminidase, a-fucosidase, a-mannosidase, and endo- -galactosidase).
- These enzymes may be able to extensively digest the surface glycans on the tumor cells, enabling immune cell access to tumor associated epitopes that are newly exposed and for which tolerance has not been induced.
- the digested tumor cells may be collected and screened for the loss of specific glycan epitopes with antibodies and lectins to confirm their removal. Once deglycosylated on is achieved, cells may be injected intramuscularly or into the peritoneal cavity of cancer patients along with alum and monophoryl lipid A adjuvants.
- the inventor has initiated a prospective, single arm efficacy trial of an adjuvanted deglycosylated tumor vaccine in canines.
- Tumor specimens (about 3 cm 3 ) were collected surgically during treatment of naive dogs that had developed either melanoma or apocrine gland anal sac adenocarcinoma (AGASACA). In some cases, draining lymph nodes were not removed to determine the efficacy of immune activation.
- Tumor cells were isolated and treated with exoglycosidases and chemical oxidation procedures to remove CFGs. Successful elimination of CFGs was confirmed by lectin binding analysis of the treated cells. The tumor cells were subjected to 5X freeze-thaw cycles to kill them and generate tumor cell lysates.
- This lysate was mixed with AS04 adjuvant (alum, monophosphoryl lipid A) in physiological saline (0.14 M). This combination is routinely employed in vaccinations against viruses and bacteria in humans. Dogs were inoculated subcutaneously at different sites on their limbs with lysates from 7-10 X 10 6 cells at 0, 2, 4 and 6 weeks.
- AS04 adjuvant alum, monophosphoryl lipid A
- EXAMPLE 1 Vaccine immunization therapy on a dog with cancer.
- FIG. 2 Radiographs of the thorax on before surgical harvest of the metastatic lymph node revealed progression of metastatic disease.
- EXAMPLE 2 Preparation of an Adjuvanted, Deglycosylated Autologous Tumor Vaccine from Canine Tumor Cells.
- the resulting dissociated tumor cells were plated out in RPMI 1640 media (Gibco) containing 10% fetal calf serum (Sigma- Aldrich), 100 units of penicillin-streptomycin mixture/ml (Gibco), Glutamax (L-alanyl-L-glutamine; 1 ml/100 ml of media; Gibco) and Fungizone (amphotericin B (1 ml/500 ml)). Tumor cells were allowed to adhere to the plate, while other cells stayed in suspension. After three days, nonadherent contaminating cells were removed, leaving about 500,000-1 million tumor cells/cm 3 tumor tissue. These tumor cells were seeded into two T-75 flasks.
- the tumor cells were expanded in culture until about 35-40 million tumor cells were obtained. [0091] To deglycosylate the tumor cells, cells were suspended in new media (2 million cells/ml) supplemented with 5 ⁇ g/ml tunicamycin (Sigma- Aldrich), 2 mM benzyl 2-acetamido-2- deoxy-a-D-galactopyranoside (Sigma- Aldrich) and D-threo-l-phenyl-2-decanoylamino-3- morpholino-l-propanol (Matreya LLC) to inhibit N-glycosylation, O-glycosylation and glycosphingolipid synthesis, respectively.
- new media (2 million cells/ml) supplemented with 5 ⁇ g/ml
- tunicamycin Sigma- Aldrich
- 2 mM benzyl 2-acetamido-2- deoxy-a-D-galactopyranoside Sigma- Aldrich
- the media was also supplemented with the following glycosidases: neuraminidase from Clostridium perfringens (New England BioLabs, 100 units/ml), ⁇ 1-4 galactosidase from Streptococcus pneumoniae (Prozyme, 10 mU/ml) and endo- ⁇ - galactosidase (QA-Bio, 30 mU/ml).
- neuraminidase from Clostridium perfringens (New England BioLabs, 100 units/ml)
- ⁇ 1-4 galactosidase from Streptococcus pneumoniae
- endo- ⁇ - galactosidase QA-Bio, 30 mU/ml
- Deglycosylated tumor cells were next pelleted by centrifugation (500xg, 10 minutes) resuspended in physiologic saline and transferred to a cryovial. The cells were pelleted again by centrifugation. The cells were subjected to five freeze-thaw cycles (-80°C, 37°C) to break the cellular membrane and generate lysates.
- AS04 Adjuvant System 04
- AS04 is a mixture of Alhydrogel® adjuvant 2% and 220 ⁇ g of synthetic monophosphoryl lipid A that induces a transient localized innate immune response that enhances adaptive immunity in humans.
- the lysate and AS04 were suspended in sterile physiological saline to a final volume of 2.2 ml. This vaccine was immediately refrigerated and stored at 4°C.
- EXAMPLE 3 Assessment of an Adjuvanted, Deglycosylated Autologous Tumor Vaccine on Metastatic Progression in Canines.
- dogs with naturally-occurring oral melanoma were enrolled into a single-arm trial to assess the efficacy of an adjuvanted, deglycosylated autologous tumor vaccine.
- dogs could be of any sex but a minimum weight of 10 kg was required.
- Dogs in the study had an oral melanoma lesion of at least 2 cm in longest diameter or metastatic lymph nodes that could be surgically resected for vaccine preparation. Dogs could be of any stage of disease progression, but a performance score of 0 or 1 with a minimum estimated life expectancy of 12 weeks was required for inclusion. Dogs could not be receiving immunosuppressive therapy. Metastatic lesions could not have been treated with radiation therapy.
- Dogs with melanoma could not have received the ONCEPT® vaccine prior to enrollment or during the trial.
- Prior chemotherapy was allowed with a three week washout prior to trial enrollment.
- Comorbidities, including kidney disease with azotemia, liver disease or hepatic enzymopathy greater than twice the upper limit of basal state, or chronic infection were not allowed.
- the resulting lysate was mixed with AS04 adjuvant (alum, monophosphoryl lipid A) in physiological saline. Dogs were inoculated subcutaneously at different sites on their limbs with lysates from 7-10 X 10 6 cells at 0, 2, 4 and 6 weeks. Prior to the first vaccine administration, and at each subsequent administration, then monthly thereafter, blood was collected for humoral and cellular assays to evaluate tumor- specific immune response. Thoracic radiographs were repeated every 2 months until 6 months, then every 3 months thereafter. Draining lymph nodes was monitored by palpation and aspiration on the same schedule as thoracic radiographs are made.
- AS04 adjuvant alum, monophosphoryl lipid A
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present disclosure provides a novel therapeutic vaccine approach that triggers a therapeutic antitumor response. The inventive approach is to selectively eliminate the carbohydrate sequences from tumor cells without affecting the tumor associated protein epitopes.
Description
CANCER IMMUNE-BASED THERAPY
FIELD
[0001] The present disclosure relates to cancer therapy, more particularly to a therapeutic vaccine that triggers a therapeutic antitumor response.
BACKGROUND
[0002] The statements in this section merely provide background information related to the present disclosure and may not constitute prior art.
[0003] Cancer is an abnormal proliferation of cells, and in many cases their dissemination, that can occur virtually anywhere in any multicellular organism (1). In 2016, there were estimated to be 1,685,210 new cases of human cancer diagnosed in the United States, excluding in situ, squamous and basal cell type carcinomas (2). The corresponding estimated number of deaths due to cancer was 595,690. According to the latest available figures, 42% of human males and 38% of all females will eventually develop cancer during their lifetime (2). The same statistical data indicate that 22.6% of men and 19.1% of females will eventually succumb to cancer (2). Classical immunization strategies have failed to block the development of metastatic cancer, and in some cases tend to actually decrease survival (3). All therapeutic cancer vaccines, with one possible exception (Provenge, sipuleucel-T) have not had any positive effect on survival (4).
[0004] Statistical data confirm that the majority of humans and companion animals do not develop lethal malignant tumors (5-8). How this majority resists the development of cancer has been a subject of debate for many years. In 1967, Nobelist F. M. Burnet proposed that a major function of the immune system is the elimination of tumor cells, a concept that he designated "immune surveillance" (9). According to this model, lymphocytes act as sentinels that recognize specific tumor associated antigens that arise from spontaneous mutations. Tumor associated antigens are also often referred to as neoantigens (10). Neoantigens enable the efficient immune destruction of tumor cells as they emerge due to mutation. According to this model, spontaneous fatal tumors arise because: (i) malignant cells had somehow managed to escape
immunosurveillance; or (ii) the immune system was compromised in some way that inhibited anti-tumor cell responses (9).
[0005] The immune surveillance model did not go unchallenged, however. A study in 1976 involving a very large number of mice and 27 different spontaneously arising tumor types suggested that malignant cells are not recognized by the immune system (11). This result led many cancer investigators to incorrectly conclude that the major problem with tumor cells was aberrant proliferation rather than immune evasion. However, reports published in the 1990s confirmed that tumor cells are genomically unstable and display many mutations. For example, a single colorectal carcinoma was identified that exhibited over 11,000 genomic alterations, suggesting that malignant cells express abundant neoantigens (12). In addition, mice deficient in specific key immune activating molecules (recombinase-activating gene, STAT, perforin, interferon-γ, and interferon- γ receptor) were also shown to have higher incidences of carcinogen-induced tumors and spontaneous epithelial carcinomas (13). These results were consistent with immunosurveillance that targets tumor cells for destruction, preventing the development of lethal cancers. A plethora of evidence now firmly supports the immune surveillance model for the prevention of cancer (14, 15).
[0006] Burnet's model immediately suggested that tumor cell vaccines should be useful for preventing the development of cancer by stimulating the immune system. However, immunization with either syngeneic or allogeneic tumor cell lysates did not prevent the development of spontaneous cancer in either humans or animal models (16, 17). To address this lack of a durable response, vaccinologists suggested that tumor antigens would be more effective if administered as part of a therapeutic rather than a preventative vaccine (18). However, the results with therapeutic vaccines have also been poor (3). Perhaps the most notable case was Canvaxin, a therapeutic human melanoma vaccine that was composed of tumor cell lysates from three allogeneic melanoma cell lines combined with a powerful adjuvant {Bacillus Calmette- Guerin; BCG) (19). Surprisingly, this vaccine yielded worse outcomes in treated patients than in controls in a large Phase III clinical trial, actually significantly decreasing survival (3).
[0007] How could such counterintuitive results be obtained if tumor cells express many different neoantigens as modern genomic analyses have unequivocally confirmed (20)? These
observations suggest that tumor cells in cancer patients must be employing a natural pathway of immune suppression to escape destruction. One natural pathway was implied in the mammalian reproductive system. In 1953, Nobel Laureate Sir Peter Medawar posed the following question: "How does the pregnant mother nourish within itself for many weeks or months a fetus that is antigenically a foreign body?" (21). The mammalian fetus is a foreign body to the mother because of the presence of paternal major histocompatibility complex (MHC) molecules. The fetus is completely foreign if development occurs in the uterus of an unrelated surrogate mother facilitated by human IVF. How female placental mammals (eutherians) can accommodate the foreign fetus has been a major question since this enigma was proposed over sixty years ago (22- 27).
[0008] Other studies in the field of reproductive immunology have revealed other immunological enigmas that are likely applicable to all placental mammals (eutherians). A good example is the observation that human sperm and eggs completely lack major histocompatibility complex (MHC) molecules known as human leukocyte antigens (HLA) (28). Because of the absence of HLA, human gametes cannot trigger allogeneic immune responses, nor are they sensitive to such responses. On the other hand, natural killer (NK) cells express specific inhibitory receptors that bind to HLA class I molecules on potential target cells. Engagement of these receptors promotes tolerance of somatic cells expressing these HLA class I molecules (29). Since human sperm and eggs lack HLA molecules, how these gametes evade NK cell responses represents another major immunological enigma.
[0009] Human sperm pose yet another major immunological enigma. Spermatogenesis is initiated in human males during puberty, long after the period of thymic education (30). Sperm proteins are specifically expressed for the first time during the onset of puberty, suggesting that they are antigenic. Such proteins are often referred to as either autoantigens or neoantigens (31, 32). Several tolerizing factors are expressed in the human male urogenital tract and seminal plasma that likely block immune responses directed against sperm autoantigens (33). However, human seminal plasma factors do not enter the uterus, but sperm have complete access to the female urogenital tract. How human sperm block adaptive immune responses directed against their neoantigens in females is yet another major immunological enigma.
[0010] The human fetoembryonic defense system (Hu-FEDS) hypothesis was initially proposed in 1996 to address these major immunological enigmas in reproduction. In this model, a specific glycoprotein designated glycodelin-A (GdA) and mucins present in the placenta, amniotic fluid and decidua were implicated as factors that suppress the maternal immune response in the pregnant uterus. These glycoconjugates were suggested to manifest their effects by employing their glycans as carbohydrate functional groups (CFGs) to block immune cell binding or interact with lectin-like receptors coupled to signal transduction proteins that modulate immune responses (34).
[0011] A pathway for the protection of HLA class I negative human sperm from NK cell was proposed in 1996 as a component of the Hu-FEDS model. HLA class I negative K562 erythroleukemia cells are efficiently lysed in NK cell cytotoxicity assays (35). However, K562 cells become completely resistant to NK cell lysis if the level of expression of a specific carbohydrate sequence known as the biantennary bisecting type (BBSCT) N-glycan is elevated on their surface (36, 37). Subsequent sequencing of the N-glycans expressed on human sperm glycoproteins combined with the binding of a lectin specific for bisecting type N-glycan (erythroagglutinating phytohemagglutinin; E-PHA) confirmed that BBSCT N-glycans are profusely expressed on the plasma membrane of human sperm (38, 39). These results are consistent with the concept that human sperm evade NK cell responses by expressing BBSCT N- glycans.
[0012] Data has also become available to explain how HLA class I negative human eggs evade NK cell lysis. There is evidence that two different types of carbohydrate sequences are protective. The outer specialized matrix of the egg known as the zona pellucida is coated with sialyl-Lewisx sequences (SLEX) (38). SLEX is a ligand for Siglec-9, a lectin-like inhibitory receptor on NK cells that bears an immunoreceptor tyro sine-based inhibitory motif (ITIM) (40). The plasma membrane of the human egg cell also stains intensely with E-PHA, indicating that glycoproteins bearing BBSCT N-glycans are likely also expressed on the surface of these germ cells.
[0013] Specific CFGs associated with human sperm could also play a role in evoking tolerance to neoantigens associated with this cell type in the female reproductive system.
Glycomic analysis of human sperm indicates that many of their glycoproteins bear terminal Lewisy sequences (41). These carbohydrate sequences are ligands for another immune lectin (DC-SIGN) that is expressed on the surface of dendritic cells (42). The binding of glycans bearing fucosylated ligands like Lewisy to DC-SIGN inhibits the development of adaptive immune responses by dendritic cells (43).
[0014] A major question is how do tumor cells circumvent immune surveillance in cancer victims? Thirty years ago, murine monoclonal antibodies (mAb) were obtained that specifically reacted with human tumor cells but not their progenitor cells. One mAb (AH-6) was bound to Lewisy while the other mAb (CSLEX) was bound to SLEX (44, 45). Lewisy and SLEX were therefore initially referred to as tumor associated carbohydrate antigens (TACAs) long before any other function was ascribed to them. About 70-80% of all human tumor cells of epithelial origin (adenocarcinomas) substantially increase the expression of SLEX and Lewisy on their surfaces (44-46). SLEX and Lewisy sequences are attached to all three major classes of glycoconjugates on human tumor cells (N-glycans, O-glycans, glycosphingolipids) (44, 47, 48). The Lewisy sequence was previously shown to be a useful target in antibody-directed radioimmunotherapy in dogs (49). BBSCT N-glycan expression is also often elevated on the surface of tumor cells arising from different organs (50)
[0015] Other major human TACAs include glycosphingolipids (globo H, GM2, GD2, GD3,) and antigens attached to N-glycans, O-glycans or glycosphingolipids (H blood group, Lewis3, sialyl-Lewisa, Tn, sialyl-Tn) (47). Compared to human melanocytes, melanoma cells overexpress gangliosides GM2, GD2, and GD3 (51). GD3 is a ligand for Siglec-7, another ITIM type receptor on NK cells that inhibits lytic responses (52). Metastatic human melanoma cells also present high levels of linear polylactosamine type sequences on their N-glycans that are undetectable in normal melanocytes (53). Similarly, elevated levels of polylactosamines are also observed on invasive colorectal, pancreatic, breast, lung, hepatocellular, ovarian and papillary cancer, but not their progenitor cells. Linear polylactosamine sequences bind specifically to galectins. Galectins have been shown to induce substantial modulatory effects on the human immune response (54, 55).
[0016] As noted earlier, glycodelin-A is a glycoprotein with substantial immune modulatory activity that is expressed in the pregnant human uterus (56). A specific CFG that has been implicated in mediating its biological activity is the fucosylated lacdiNAc sequence (57). Recent analyses indicate that this sequence is highly expressed on poorly differentiated human colorectal cancer cells with high metastatic potential (48). In summary, many and perhaps all of the CFGs that protect human gametes and the developing eutherian in utero from the maternal immune response are also being deployed by mammalian tumor cells to protect them from immune surveillance (58).
[0017] Much less is known about the glycosylation of canine and feline tumor cells than human tumor cells. Nonetheless, there is evidence that SLEX expression is upregulated on about 70% of all canine and feline mammary gland tumors (59-61). Similarly, Lewisy is expressed on 52% of the carcinomas of mammary, prostatic, bronchogenic, nasal, hepatic, rectal, tonsillar squamous, lacrimal gland, and nasal planum squamous origin (62). A substantial increase in the expression of T and Tn antigens were also observed on canine mammary tubulopapillary carcinomas as compared to simple benign adenomas in dogs (63). In summary, there are indications that, like human tumor cells, similar carbohydrate sequences are being expressed during oncogenic development in dogs and cats. It is likely that they are also being used in a similar fashion to protect canine and feline-tumor cells from destruction.
[0018] Major shifts in the glycosylation of tumor cells constitute a specific hallmark of cancer (64). Substantial data indicate that tumor cells begin to express the same CFGs that are employed to protect the gametes and the developing fetus in utero. The evidence indicates that this pattern of altered glycoconjugate expression acts as a "glycan shield" that protects aggressive tumor cells from the adaptive immune response. In essence, this shield enables these tumor cells to couple their survival to the reproductive imperative. This glycan shield likely exists in all eutherians, and in lower species in the form of protection for gametes (56). By specifically attacking this shield, we enable immune effector cells to detect the tumor neoantigens. It is very likely that once immune cells can clearly "see" these neoantigens, they lose their ability to be inhibited by these CFGs, and attack the tumor cells, leading to their lysis
and the destruction of solid tumors. Our data clearly supports this strategy as a viable immunotherapy for mammalian cancer.
[0019] Therefore, there is a need to provide an antitumor therapy to disrupt the glycan shielding on the tumor cells of humans and/or companion animals to activate the immune response against the tumor cells.
[0020] The teaching and content of the following references is hereby incorporated by references herein.
1. Hernandez-Divers, S. M., and Garner, M. M. (2003) Neoplasia of reptiles with an emphasis on lizards. Vet Clin North Am ExotAnim Pract 6, 251-273
2. Society, A. C. (2016) Cancer Facts and Figures 2016. American Cancer Society, found on the web at cancer.org
3. Goldman, B., and DeFrancesco, L. (2009) The cancer vaccine roller coaster. Nature biotechnology 27 ', 129-139
4. Cheever, M. A., and Higano, C. S. (2011) PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clinical cancer research : an official journal of the American Association for Cancer Research 17, 3520-3526
5. ACS (2013) Cancer Facts and Figures. American Cancer Society
6. Bronson, R. T. (1982) Variation in age at death of dogs of different sexes and breeds. American journal of veterinary research 43, 2057-2059
7. Adams, V. J., Evans, K. M., Sampson, J., and Wood, J. L. (2010) Methods and mortality results of a health survey of purebred dogs in the UK. J Small Anim Pract 51, 512-524
8. Blackwood, L. (2013) Cats with cancer: where to start. J Feline Med Surg 15, 366-377
9. Burnet, M. (1957) Cancer; a biological approach. I. The processes of control. Br Med J I, 779-786
10. Huebner, R. J., Casey, M. J., Chanock, R. M., and Schell, K. (1965) Tumors induced in hamsters by a strain of adenovirus type 3 : sharing of tumor antigens and "neoantigens" with those produced by adenovirus type 7 tumors. Proceedings of the National Academy of Sciences of the United States of America 54, 381-388
11. Hewitt, H. B., Blake, E. R., and Walder, A. S. (1976) A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. British journal of cancer 33, 241-259
12. Stoler, D. L., Chen, N., Basik, M., Kahlenberg, M. S., Rodriguez-Bigas, M. A., Petrelli, N. J., and Anderson, G. R. (1999) The onset and extent of genomic instability in sporadic colorectal tumor progression. Proceedings of the National Academy of Sciences of the United States of America 96, 15121-15126
13. Schreiber, R. D., Old, L. J., and Smyth, M. J. (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570
14. Marcus, A., Gowen, B. G., Thompson, T. W., Iannello, A., Ardolino, M., Deng, W., Wang, L., Shifrin, N., and Raulet, D. H. (2014) Recognition of tumors by the innate immune system and natural killer cells. Advances in immunology 122, 91-128
15. Gross, E., Sunwoo, J. B., and Bui, J. D. (2013) Cancer immunosurveillance and immunoediting by natural killer cells. Cancer J 19, 483-489
16. Stewart, T. H., and Orizaga, M. (1971) The presence of delayed hypersensitivity reactions in patients toward cellular extracts of their malignant tumors. 3. The frequency, duration, and cross reactivity of this phenomenon in patients with breast cancer, and its correlation with survival. Cancer 28, 1472-1478
17. LaSalle, B. (1968) Veterinary vaccines. Natl Cancer Inst Monogr 29, 515-522
18. Curigliano, G., Spitaleri, G., Pietri, E., Rescigno, M., de Braud, F., Cardillo, A., Munzone, E., Rocca, A., Bonizzi, G., Brichard, V., Orlando, L., and Goldhirsch, A. (2006) Breast cancer vaccines: a clinical reality or fairy tale? Ann Oncol 17, 1 '50-762
19. Morton, D. L., Hsueh, E. C, Essner, R., Foshag, L. J., O'Day, S. J., Bilchik, A, Gupta, R. K., Hoon, D. S., Ravindranath, M., Nizze, J. A., Gammon, G., Wanek, L. A., Wang, H. J., and Elashoff, R. M. (2002) Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Annals of surgery 236, 438-448; discussion 448-439
20. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C, Aparicio, S. A., Behjati, S., Biankin, A. V., Bignell, G. R., Bolli, N., Borg, A., Borresen-Dale, A. L., Boyault, S., Burkhardt, B., Butler, A. P., Caldas, C, Davies, H. R., Desmedt, C, Eils, R., Eyfjord, J. E., Foekens, J. A., Greaves,
M., Hosoda, F., Hutter, B., Ilicic, T., Imbeaud, S., Imielinski, M., Jager, N., Jones, D. T., Jones, D., Knappskog, S., Kool, M., Lakhani, S. R., Lopez-Otin, C, Martin, S., Munshi, N. C, Nakamura, H., Northcott, P. A., Pajic, M., Papaemmanuil, E., Paradiso, A., Pearson, J. V., Puente, X. S., Raine, K., Ramakrishna, M., Richardson, A. L., Richter, J., Rosenstiel, P., Schlesner, M, Schumacher, T. N., Span, P. N., Teague, J. W., Totoki, Y., Tutt, A. N., Valdes- Mas, R., van Buuren, M. M., van 't Veer, L., Vincent-Salomon, A., Waddell, N., Yates, L. R., Australian Pancreatic Cancer Genome, L, Consortium, I. B. C, Consortium, I. M.-S., PedBrain, L, Zucman-Rossi, J., Futreal, P. A., McDermott, U., Lichter, P., Meyerson, M., Grimmond, S. M., Siebert, R., Campo, E., Shibata, T., Pfister, S. M., Campbell, P. J., and Stratton, M. R. (2013) Signatures of mutational processes in human cancer. Nature 500, 415-421
21. Medawar, P. (1953) Some immunological and endocrinological problems raised by the evolution of viviparity in vertebrates. Symp. Soc. Exp. Biol. VII, 320-338
22. PrabhuDas, M., Bonney, E., Caron, K., Dey, S., Erlebacher, A., Fazleabas, A., Fisher, S., Golos, T., Matzuk, M., McCune, J. M., Mor, G., Schulz, L., Soares, M., Spencer, T., Strominger, J., Way, S. S., and Yoshinaga, K. (2015) Immune mechanisms at the maternal-fetal interface: perspectives and challenges. Nature immunology 16, 328-334
23. Moffett, A., and Loke, C. (2006) Immunology of placentation in eutherian mammals. Nature reviews. Immunology 6, 584-594
24. Trowsdale, J., and Betz, A. G. (2006) Mother's little helpers: mechanisms of maternal- fetal tolerance. Nature immunology 7, 241-246
25. Prins, J. R., Gomez-Lopez, N., and Robertson, S. A. (2012) Interleukin-6 in pregnancy and gestational disorders. Journal of reproductive immunology 95, 1-14
26. Arck, P. C, and Hecher, K. (2013) Fetomaternal immune cross-talk and its consequences for maternal and offspring's health. Nature medicine 19, 548-556
27. Erlebacher, A. (2013) Mechanisms of T cell tolerance towards the allogeneic fetus. Nature reviews. Immunology 13, 23-33
28. Hutter, H., and Dohr, G. (1998) HLA expression on immature and mature human germ cells. Journal of reproductive immunology 38, 101-122
29. Long, E. O., Kim, H. S., Liu, D., Peterson, M. E., and Rajagopalan, S. (2013) Controlling natural killer cell responses: integration of signals for activation and inhibition. Annual review of immunology 31, 227-258
30. Kourilsky, P., and Claverie, J. M. (1989) MHC restriction, alloreactivity, and thymic education: a common link? Cell 56, 327-329
31. Tung, K. S., Teuscher, C, and Meng, A. L. (1981) Autoimmunity to spermatozoa and the testis. Immunological reviews 55, 217-255
32. Tung, K. S., Fusi, F., and Teuscher, C. (2002) Autoimmune disease of the spermatozoa, ovary and testis. In: N., T. A., and Bona, C, eds. The Molecular Pathology of Autoimmune Diseases, pp. 1031-1045, Routledge Publishers
33. Clark, G. F., and Schust, D. J. (2013) Manifestations of immune tolerance in the human female reproductive tract. Frontiers in immunology 4, 26
34. Clark, G. F., Oehninger, S., Patankar, M. S., Koistinen, R., Dell, A., Morris, H. R., Koistinen, H., and Seppala, M. (1996) A role for glycoconjugates in human development: the human fetoembryonic defence system hypothesis. Human reproduction 11, 467-473
35. Kay, H. D., Fagnani, R., and Bonnard, G. D. (1979) Cytotoxicity against the K562 erythroleukemia cell line by human natural killer ( K) cells which do not bear free Fc receptors for IgG. International journal of cancer. Journal international du cancer 24, 141-150
36. el Ouagari, K., Teissie, J., and Benoist, H. (1995) Glycophorin A protects K562 cells from natural killer cell attack. Role of oligosaccharides. The Journal of biological chemistry 270, 26970-26975
37. Yoshimura, M., Ihara, Y., Ohnishi, A., Ijuhin, N., Nishiura, T., Kanakura, Y., Matsuzawa, Y., and Taniguchi, N. (1996) Bisecting N-acetylglucosamine on K562 cells suppresses natural killer cytotoxicity and promotes spleen colonization. Cancer research 56, 412-418
38. Pang, P. C, Chiu, P. C, Lee, C. L., Chang, L. Y., Panico, M., Morris, H. R., Haslam, S. M., Khoo, K. H., Clark, G. F., Yeung, W. S., and Dell, A. (2011) Human sperm binding is mediated by the sialyl-Lewisx oligosaccharide on the zona pellucida. Science 333, 1761-1764
39. Patankar, M. S., Ozgur, K., Oehninger, S., Dell, A., Morris, H., Seppala, M., and Clark, G. F. (1997) Expression of glycans linked to natural killer cell inhibition on the human zona pellucida. Molecular human reproduction 3, 501-505
40. Angata, T., and Varki, A. (2000) Cloning, characterization, and phylogenetic analysis of siglec-9, a new member of the CD33 -related group of siglecs. Evidence for co-evolution with sialic acid synthesis pathways. The Journal of biological chemistry 275, 22127-22135
41. Pang, P. C, Tissot, B., Drobnis, E. Z., Sutovsky, P., Morris, H. R., Clark, G. F., and Dell, A. (2007) Expression of bisecting type and Lewisx/Lewisy terminated N-glycans on human sperm. The Journal of biological chemistry 282, 36593-36602
42. Garcia- Vallejo, J. J., and van Kooyk, Y. (2013) The physiological role of DC-SIGN: a tale of mice and men. Trends in immunology 34, 482-486
43. Gringhuis, S. I, den Dunnen, J., Litjens, M., van der Vlist, M., and Geijtenbeek, T. B. (2009) Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori. Nature immunology 10, 1081-1088
44. Fukushima, K., Hirota, M., Terasaki, P. L, Wakisaka, A., Togashi, H., Chia, D., Suyama, N., Fukushi, Y., Nudelman, E., and Hakomori, S. (1984) Characterization of sialosylated Lewisx as a new tumor-associated antigen. Cancer research 44, 5279-5285
45. Abe, K., McKibbin, J. M., and Hakomori, S. (1983) The monoclonal antibody directed to difucosylated type 2 chain (Fucal-2Galbl-4[Fucal-3]GlcNAc; Y Determinant). The Journal of biological chemistry 258, 11793-11797
46. Hellstrom, L, Garrigues, H. J., Garrigues, U., and Hellstrom, K. E. (1990) Highly tumor- reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer research 50, 2183-2190
47. Hakomori, S. (2001) Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Advances in experimental medicine and biology 491, 369-402
48. Sethi, M. K., Thaysen-Andersen, M., Smith, J. T., Baker, M. S., Packer, N. H., Hancock, W. S., and Fanayan, S. (2014) Comparative N-glycan profiling of colorectal cancer cell lines reveals unique bisecting GlcNAc and alpha-2, 3 -linked sialic acid determinants are associated
with membrane proteins of the more metastatic/aggressive cell lines. Journal of proteome research 13, 277-288
49. Bryan, J. N., Jia, F., Mohsin, H., Sivaguru, G., Anderson, C. J., Miller, W. H., Henry, C. J., and Lewis, M. R. (2011) Monoclonal antibodies for copper-64 PET dosimetry and radioimmunotherapy. Cancer Biol Ther 11, 1001-1007
50. Christiansen, M. N., Chik, J., Lee, L., Anugraham, M., Abrahams, J. L., and Packer, N. H. (2013) Cell surface protein glycosylation in cancer. Proteomics
51. Hakomori, S. (1984) Tumor-associated carbohydrate antigens. Annual review of immunology !, 103-126
52. Nicoll, G, Avril, T., Lock, K., Furukawa, K., Bovin, N., and Crocker, P. R. (2003) Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7- dependent and -independent mechanisms. European journal of immunology 33, 1642-1648
53. Kinoshita, M., Mitsui, Y., Kakoi, N., Yamada, K., Hayakawa, T., and Kakehi, K. (2014) Common glycoproteins expressing polylactosamine-type glycans on matched patient primary and metastatic melanoma cells show different glycan profiles. Journal of proteome research 13, 1021-1033
54. Ruvolo, P. P. (2016) Galectin-3 as a guardian of the tumor microenvironment. Biochimica et Biophysica Acta 1863, 427-433
55. Boligan, K. F., Mesa, C, Fernandez, L. E., and von Gunten, S. (2015) Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense. Cellular and Molecular Life Sciences 72, 1231-1248.
56. Dell, A., Morris, H. R., Easton, R. L., Panico, M., Patankar, M., Oehniger, S., Koistinen, R., Koistinen, H., Seppala, M., and Clark, G. F. (1995) Structural analysis of the oligosaccharides derived from glycodelin, a human glycoprotein with potent immunosuppressive and contraceptive activities. The Journal of biological chemistry 270, 24116-24126.
57. Clark, G. F., Dell, A., Morris, H. R., Patankar, M., Oehninger, S., and Seppala, M. (1997) Viewing AIDS from a glycobiological perspective: potential linkages to the human fetoembryonic defence system hypothesis. Molecular human reproduction 3, 5-13
58. Clark, G. F. (2014) The role of glycans in immune evasion: the human fetoembryonic defence system hypothesis revisited. Molecular human reproduction 20, 185-199
59. Janke, L., Carlson, C. S., and St Hill, C. A. (2010) The novel carbohydrate tumor antigen C2-0-sLe x is upregulated in canine gastric carcinomas. Veterinary pathology 47, 455-461
60. Nakagawa, T., Uyama, R., Ohashi, E., Takahashi, T., Hong, S. H., Mochizuki, M., Matsunaga, S., Nishimura, R., and Sasaki, N. (2002) The expression of sialyl Lewis X in canine and feline mammary gland tumors. The Journal of veterinary medical science / the Japanese Society of Veterinary Science 64, 949-952
61. Pinho, S. S., Matos, A. J., Lopes, C, Marcos, N. T., Carvalheira, J., Reis, C. A., and Gartner, F. (2007) Sialyl Lewis x expression in canine malignant mammary tumours: correlation with clinicopathological features and E-Cadherin expression. BMC Cancer 7, 124
62. Henry, C. J., Buss, M. S., Hellstrom, L, Hellstrom, K. E., Brewer, W. G., Bryan, J. N., and Siegall, C. B. (2005) Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 11, 751-755
63. Nowak, M., Madej, J., Dziegiel, P., Lopuszynski, W., Rodo, A., and Ugorski, M. (2009) Tumor-associated carbohydrate antigens: Sialyl Lea and T/Tn antigens in canine mammary tumors. Veterinary pathology 46, 222-226
64. Vajaria, B. N., and Patel, P. S. (2016) Glycosylation: a hallmark of cancer? Glycoconjugate journal (currently epub ahead of print)
SUMMARY
[0021] The present disclosure provides a novel therapeutic vaccine approach that triggers a therapeutic antitumor response. More specifically, according to one embodiment of the disclosure, the method may comprise the step of inoculating of a subject (human or other mammal) with autologous deglycosylated tumor cell lysates to evoke an immune-based antitumor response. In some forms, the potency of the lysates is inversely correlated with the stage of the cancer, the age of the subject, the immune status of said subject (the cancer patient), or a combination of these factors.
[0022] According to another embodiment of the disclosure, the method may comprise the step of inoculating of a healthy subject (human or other mammal) with syngeneic or HLA
class I negative deglycosylated metastatic tumor cell lysates to evoke a durable antitumor response directed against neoantigens to prevent or greatly impede the development of aggressive cancer. This immunization approach may enable all humans and other mammals to resist the development of metastatic cancer for as long as immunocompetence is maintained. Generally speaking, immunocompetence is maintained in the great majority of humans until at least age 80, unless the person is a smoker, engages in excessive alcohol consumption, or suffers from a known genetic or acquired immunodeficiency.
I. Methods
(a) Preparing an Adjuvanted, Deglycosylated Autologous Tumor Vaccine and Treatment
[0023] One embodiment of the present disclosure provides methods of preparing an adjuvanted, deglycosylated autologous tumor vaccine and treatment that may be derived from the tumor cells of a patient. The method comprises harvesting and isolating cancer cells from patient cancers for incubation with one or more deglycosylation agents and/or inhibitors wherein after the incubation a majority of the cancer cell membrane is deglycosylated. As described herein, "deglycosylated" refers to the disruption of glycolytic linkages, inhibition of forming glycolytic linkages, or disruption and inhibition of forming glycolytic linkages on at least a majority of the cancer cell membrane. Deglycosylation disrupts the carbohydrate functional groups (CFGs) and subsequent glycan shielding to expose the neoantigens and thereby permit the immune system to detect and attack cancer cells once the composition is administered to the patient. The method also comprises combining deglycosylated cancer cell lysate with at least one additional component selected from the group consisting of pharmaceutically-acceptable carriers, adjuvants, diluents, preservatives, antibiotics, and combinations thereof. In some forms, the cancer cells are tumor cells and in other forms, the cancer cells are from liquid cancers such as leukemia. It is understood that when "tumor cells" are referenced herein, it also encompasses cells from liquid cancers.
(i) Harvesting cancerous tissues and liquid cancers for isolated cancer cells
[0024] Generally speaking, methods of harvesting cancer cells from patients are known in the art. In certain embodiments, the patient refers to an animal that has presented with cancer. In certain embodiments, the patient may be a mammal, and in some embodiments, the patient
may be a human. In certain embodiments, a patient may be a livestock animal (horse, cow, pig, sheep, etc.) or a companion animal (dog, cat, etc.). In a particular embodiment, the patient may be canine.
[0025] In one aspect of the present disclosure, the patient may have cancer at any stage of disease progression. In one embodiment, the patient may have Stage I-IV cancer. In another embodiment, the patient has Stage I-III cancer. In another embodiment, the patient has Stage I-II cancer. In another embodiment, the patient has Stage I cancer. In another embodiment, the cancer may be a primary cancer, a metastases, or primary cancer and metastases. In yet another embodiment, the cancer may be a solid cancer. In still another embodiment, the cancer may be a liquid cancer. Non-limiting examples of cancer types include carcinomas, sarcomas, lymphomas, leukemias, myelomas and mixed types (e.g., blastomas).
[0026] In one embodiment, cancer cells may be harvested from a solid tumor, a metastatic node or a solid tumor and a metastatic node, or a liquid cancer. In one embodiment, a harvested tumor cell source may be less than about 0.2 cm3 to at least about 20 cm3 or greater, at least about 2 cm3 to at least about 18 cm3 or greater, at least about 3 cm3 to at least about 15 cm3 or greater, at least about 4 cm3 to at least about 12 cm3 or greater, at least about 5 cm3 to at least about 10 cm3 or greater, or at least about 6 cm3 to at least about 8 cm3 or greater. A harvested tumor cell source may be at least about 0.2 cm3 or greater, at least about 0.3 cm3 or greater, at least about 0.4 cm3 or greater, at least about 0.5 cm3 or greater, at least about 1 cm3 or greater, at least about 2 cm3 or greater, at least about 3 cm3 or greater, at least about 4 cm3 or greater, at least about 5 cm3 or greater, at least about 6 cm3 or greater, at least about 7 cm3 or greater, at least about 8 cm3 or greater, at least about 9 cm3 or greater, at least about 10 cm3 or greater, at least about 11 cm3 or greater, at least about 12 cm3 or greater, at least about 13 cm3 or greater, at least about 14 cm3 or greater, at least about 15 cm3 or greater, at least about 16 cm3 or greater, at least about 17 cm3 or greater, at least about 18 cm3 or greater, at least about 19 cm3 or greater, or at least about 20 cm3 or greater. In certain embodiments, a harvested tumor cell source may be at least about 0.2 cm3 to about 0.3 cm3 or greater, at least about 0.3 cm3 to about 0.4 cm3 or greater, at least about 0.4 cm3 to about 0.5 cm3 or greater, at least about 0.5 cm3 to about 1 cm3 or greater, at least about 1 cm3 to about 2 cm3 or greater, at least about 2 cm3 to about 3 cm3 or greater, at
least about 3 cm3 to about 4 cm3 or greater, at least about 4 cm3 to about 5 cm3 or greater, at least about 5 cm3 to about 6 cm3 or greater, at least about 6 cm3 to about 7 cm3 or greater, at least about 7 cm3 to about 8 cm3 or greater, at least about 8 cm3 to about 9 cm3 or greater, at least about 9 cm3 to about 10 cm3 or greater, at least about 10 cm3 to about 11 cm3 or greater, at least about 11 cm3 to about 12 cm3 or greater, at least about 12 cm3 to about 13 cm3 or greater, at least about 13 cm3 to about 14 cm3 or greater, at least about 14 cm3 to about 15 cm3 or greater, at least about 15 cm3 to about 16 cm3 or greater, at least about 16 cm3 to about 17 cm3 or greater, at least about 17 cm3 to about 18 cm3 or greater, 18 cm3 to about 19 cm3 or greater, or at least about 19 cm3 to about 20 cm3 or greater.
[0027] It is appreciated that one skilled in the art would be able to select an appropriate method for separating tumor cells from non-tumor cell types for purposes of the present disclosure. It is also appreciated that one skilled in the art would be able to select an appropriate method to culture and expand the isolated tumor cells for purposes of the present disclosure. In one embodiment, a harvested tumor cell source may have enough cells to be isolated and amplified. Preferably, the harvested tumor cell source should have between at least about 0.5 million cells to at least about 60 million cells or greater, at least about 5 million cells to at least about 55 million cells or greater, at least about 10 million cells to at least about 50 million cells or greater, at least about 15 million cells to at least about 50 million cells or greater, at least about 20 million cells to at least about 50 million cells or greater, at least about 25 million cells to at least about 50 million cells or greater, at least about 30 million cells to at least about 40 million cells or greater, or at least about 45 million cells to at least about 45 million cells or greater. In one embodiment, tumor cells may be expanded in culture to obtain at least about 0.5 million cells, at least about 1 million cells, at least about 5 million cells, at least about 10 million cells, at least about 15 million cells, at least about 20 million cells, at least about 25 million cells, at least about 30 million cells, 35 million cells, at least about 40 million cells, at least about 45 million cells, at least about 50 million cells, at least about 55 million cells, at least about 60 million cells, or greater. In another embodiment, tumor cells may be expanded in culture to obtain at least about 0.5 million cells to at least about 1 million cells, at least about 1 million cells to at least about 5 million cells, at least about 5 million cells to at least about 10 million cells, at least about 10 million cells to at least about 15 million cells, at least about 15 million
cells to at least about 20 million cells, at least about 20 million cells to at least about 25 million cells, at least about 25 million cells to at least about 30 million cells, at least about 30 million cells to at least about 35 million cells, 35 million cells to at least about 40 million cells, at least about 40 million cells to at least about 45 million cells, at least about 45 million cells to at least about 50 million cells, at least about 50 million cells to at least about 55 million cells, at least about 55 million cells to at least about 60 million cells.
(ii) Incubation with deglycosylating agents
[0028] A method of the present disclosure compromises incubating tumor cells with one or more deglycosylating agents and/or glycosylation inhibitors, wherein after the incubation a majority of tumor cell membrane is deglycosylated. In preferred forms, a majority or at least 50% of the tumor cell membrane is deglycosylated. In other preferred forms, at least about 55% or more of the tumor cell membrane is deglycosylated. More preferably, at least about 65% or more of the tumor cell membrane is deglycosylated. Still more preferably, at least about 75% or more of the tumor cell membrane is deglycosylated. Still more preferably, at least about 85% or more of the tumor cell membrane is deglycosylated. Ideally, at least about 95% or more of the tumor cell membrane is deglycosylated. In one embodiment, at least about 55% to 95% or greater, at least about 65% to 95% or greater, at least about 75% to 95% or greater, at least about 85%) to 95% or greater, or at least about 90% to 95% or greater of tumor cell membrane is deglycosylated. The percentage of tumor cell membrane that is deglycosylated refers to the percentage of CFGs or glycan shield that is disrupted, destroyed, or prevented from forming.
[0029] In a preferable embodiment, tumor cells may maintain viability after incubation with one or more deglycosylating agents and/or glycosylation inhibitors. In another embodiment, tumor cells maintain at least about 85% or greater, at least about 90% or greater, at least about 95% or greater, at least about 98% or greater, viability after incubation with one or more deglycosylating agents and/or glycosylation inhibitors. In another embodiment, the membrane of the tumor cell maintains integrity after incubation with one or more deglycosylating agents and/or glycosylation inhibitors. In another embodiment, the membrane of the tumor cell maintains at least about 85% or greater, at least about 90% or greater, at least about 95% or greater, at least about 98% or greater, integrity after incubation with one or more
deglycosylating agents and/or glycosylation inhibitors in comparison to a tumor cell that has not been incubated with one or more deglycosylation agents and/or glycosylation inhibitors. In one embodiment, membrane permeability of tumor cells after incubation with one or more deglycosylation agents and/or glycosylation inhibitors is increased compared to membranes of tumors cells not incubated with one or more deglycosylation agents and/or glycosylation inhibitors. In preferred embodiments, membrane permeability may be increased at least about 10% or greater, at least about 15%> or greater, at least about 20% or greater, at least about 25% or greater, at least about 30%> or greater, at least about 35% or greater, at least about 40% or greater, at least about 45% or greater, at least about 50% or greater, at least about 55% or greater, at least about 60%) or greater, at least about 65% or greater, at least about 70% or greater, at least about 75%) or greater, at least about 80% or greater, at least about 85% or greater, at least about 90% or greater, at least about 95% or greater, or at least about 98% or greater compared to cell membranes of tumor cells not incubated with one or more deglycosylation agents and/or glycosylation inhibitors. In another embodiment, the cell membrane permeability of tumor cells after incubation with one or more deglycosylation agents and/or glycosylation inhibitors may be increased at least about 10% to 98% or greater, at least 25% to 98% or greater, or at least 50% to 95%) or greater compared to cell membranes of tumor cells not incubated with one or more deglycosylation agents and/or glycosylation inhibitors.
[0030] In one embodiment, N-linked glycosylation of the tumor cell membrane may be disrupted. In another embodiment, O-linked glycosylation of the tumor cell membrane may be disrupted. In yet another embodiment, C-linked glycosylation of the tumor cell membrane may be disrupted. In still another embodiment, glypiation of the tumor cell membrane may be disrupted. In another embodiment, O-linked glycosylation may be disrupted. In another embodiment multiple glycosidic linkages on the tumor cell membrane may be disrupted comprising of N-, 0-, and C-linked glycosylation, glypiation, and phosphoglycosylation.
[0031] In one embodiment, deglycosylating agents may be one or more deglycosylating enzymes. As used herein, a "deglycosylating enzyme" refers to an enzyme that modifies or removes glycans from glycoproteins presented on the tumor cell membrane. In one embodiment, one or more deglycosylating enzymes may be a glycoside hydrolase with an EC number of EC
3.2.1. In another embodiment, deglycosylating enzymes may be a neuraminidase with an EC number of EC 3.2.1.18. In another embodiment, deglycosylating enzymes may be a galactosidase with an EC number of EC 3.2.1.23. In still another embodiment, deglycosylating enzymes may be an exoglycosidase with an EC number of EC 3.2.1.25. In another embodiment, deglycosylating enzymes may be an endoglycosidase with an EC number of EC 3.2.1.96. In another embodiment, deglycosylating enzymes may be an O-Glycosidase with an EC number of EC 3.2.1.97. In yet another embodiment, deglycosylating enzymes may be an amidase with an EC number of EC 3.5.1.52. In certain embodiments, a deglycosylating enzyme may be selected from the non-limiting group consisting of a Clostridium perfringens neuraminidase, Vibrio cholerae neuraminidase, Arthrobacter ureafaciens neuraminidase, Streptococcus pneumonia neuraminidase, Enterococcus faecalis O-Glycosidase, Streptococcus pneumonia β1-4 galactosidase, recombinant endo-P-galactosidase, and recombinant PNGase F. One of skill in the art would understand that the amount of the one or more deglycosylating enzymes used is generally determined by the volume of tumor cells to be deglycosylated. In certain embodiments, tumor cells may be incubated with at least two, at least three, at least four, at least five, or at least six or more distinct deglycosylating enzymes.
[0032] In one embodiment, deglycosylating agents may be one or more glycosylation inhibitors. As used herein, a "glycosylation inhibitor" refers to a compound that blocks glycosylation of proteins on the tumor cell membrane. In one embodiment, one or more glycosylation inhibitors may be a natural product. In another embodiment, one or more glycosylation inhibitors may be a synthesized product. In another embodiment, one or more glycosylation inhibitors may interfere with the steps involved in the process of glycosylation. In another embodiment, one or more glycosylation inhibitors may inhibit N-glycosylation synthesis. In another embodiment, one or more glycosylation inhibitors may inhibit O-glycosylation synthesis. In another embodiment, one or more glycosylation inhibitors may inhibit glycosphingolipid synthesis. In another embodiment, one or more glycosylation inhibitors may block glycosyltransferase activity. In another embodiment, one or more glycosylation inhibitors may block glucosylceramide synthetase activity. In another embodiment, one or more glycosylation inhibitors may belong to a class of nucleoside antibiotics. In another embodiment, one or more glycosylation inhibitors may be a plant alkaloid. In certain embodiments, a
glycosylation inhibitor may be selected from the non-limiting group consisting of tunicamycin, amphomycin, castanospermine, deoxynojirimycin, australine, swainsonine, deoxymannojirimycin, kifunensin, benzyl 2-acetamido-2-deoxy-a-D-galactopyranoside, D-threo- l-phenyl-2-decanoylamino-3-morpholino-l-propanol, PUGNAc, NAG-thiazoline, GlcNAcstatin, N-butyldeoxynojirimycin, and Neu5Ac-2-ene. One of skill in the art would understand that the concentration of the one or more glycosylation inhibitors used should be determined by the volume of tumor cells to be deglycosylated. In certain embodiments, tumor cells may be incubated with at least two, at least three, at least four, at least five, or at least six or more glycosylation inhibitors.
[0033] In some preferred embodiments, one or more deglycosylating enzymes may be combined with one or more glycosylation inhibitors as described above and each are referred to herein as "deglycosylating agents".
[0034] To deglycosylate tumor cells, cells may be suspended in cell culture media containing one or more deglycosylating agents and/or glycosylation inhibitors. In one embodiment, the tumor cells may be incubated with one or more deglycosylating agents and/or glycosylation inhibitors for a time sufficient to deglycosylate the tumor cell membrane as described above. In some instances, the incubation period may be for at least about 30 minutes, 1 hour, 2 hours, 3 hours, at least 4 hours, at least 5 hours, or greater, as well as the ranges created by two or more of these options (i.e. 30 minutes to 5 hours, 2 hours to 4 hours, 1 hour to 5 hours, etc.). In another embodiment, the tumor cells may be incubated with one or more deglycosylating agents and/or glycosylation inhibitors at an appropriate temperature sufficient to permit deglycosylation of the tumor cell membrane as described above. In some preferred forms, the incubation temperature may be about 12°C to 42°C, 15°C to 42°C, 20°C to 42°C, 25°C to 42°C, 32°C to 42°C, at about 34°C to 40°C, or at about 36°C to 38°C. In another embodiment, the incubation period may be stopped by washing the tumor cells in order to remove the deglycosylating agents and/or glycosylation inhibitors from the tumor cells. It is appreciated that one skilled in the art would be able to select an appropriate method for washing tumor cells for purposes of the present disclosure.
[0035] Another embodiment of the present disclosure compromises resuspending tumor cells in an aqueous buffer after washing the cells. In one embodiment, the aqueous buffer may be sodium phosphate buffer. In one embodiment, the aqueous buffer may contain a solute. In certain embodiments, the solute may be at least about 0.3 M to 0.1 M, at least about 0.2 M to 0.15 M, or at least about 0.15 M of a chloride, preferably sodium chloride. In another embodiment, the pH of the aqueous buffer may be about 4 to 7, may be about 5.5 to 6.5, or may be at least about 6. In another embodiment, the aqueous buffer may contain a gentle oxidizing agent. In some embodiments, the gentle oxidizing agent may be present in a sufficient amount to deglycosylate the tumor cell membrane. In certain embodiments, the gentle oxidizing agent may be present at least about 5 mM to 100 mM, 10 mM to 40 mM, at least about 40 mM to 75 mM, at least about 45 mM to 60 mM, or at least about 50 mM. In yet another embodiment, the resuspended tumor cells may be incubated in an aqueous buffer containing a gentle oxidizing agent for a time sufficient to deglycosylate the tumor cell membrane. In some preferred embodiments, the incubation time may be at least 0.5 to at least 3 hours, about at least 0.5 to 2 hours, or about at least 1 hour. In certain embodiments, the incubation with a gentle oxidizing agent may occur at a temperature that is sufficient to deglycosylate the tumor cell membrane. In preferred embodiments, the incubation temperature is between about 15°C to 35°C, 20°C to 32°C, at least 20°C to 30°C, at least 22°C to 25°C, or at least 23°C. In other embodiments, the incubation may occur in the absence of light. In some embodiments, the gentle oxidizing agent may be sodium metaperiodate. In another embodiment, the incubation of resuspended tumor cells in an aqueous buffer containing a gentle oxidizing agent may be terminated. In some embodiments, oxidation may be terminated by addition of a solution known to end the oxidation process. In preferred forms, the termination solution is preferably selected from the group, sodium sulfite, sodium bicarbonate, glycerol, or ethylene glycol. In a preferred embodiment, oxidation may be terminated by addition of ethylene glycol. In another preferred embodiment, the incubation of resuspended tumor cells in an aqueous buffer containing a gentle oxidizing agent may be terminated by the addition of at least about 25 μΐ to 75 μΐ, 45 μΐ to 55 μΐ, or 50 μΐ of ethylene glycol per milliliter of aqueous buffer.
(iii) Lysis of deglycosylated tumor cells and storage thereof
[0036] A method of the present disclosure compromises lysing tumor cells following incubation with one or more deglycosylating agents, wherein after tumor cell lysis, the cellular lysate is stored. It is appreciated that one skilled in the art would be able to select an appropriate method for lysing tumor cells for purposes of the present disclosure. A non-limiting example of a method of tumor cell lysis may be that tumor cells undergo one or more freeze-thaw cycles. In certain embodiments, tumor cells may be frozen at least about -70°C to -90°C, at least about - 75°C to -85°C, or at least about -80°C. In other certain embodiments, tumor cells may be thawed at least about 20°C to 50°C, at least about 35°C to 40°C, or at least about 37°C. In one embodiment, tumor cells may be subjected to about 2 to 7 freeze-thaw cycles, about 3 to 6 freeze-thaw cycles, about 4 to 5 freeze-thaw cycles, or about 5 freeze-thaw cycles.
[0037] Methods of storing tumor cells and/or lysed tumor cells are known in the art.
Lysed tumor cells may be immediately stored between about 2°C to 8°C, about 3°C to 5°C, about 4°C to 5, or about 4°C. In another embodiment, lysed tumor cells may be stored for up to 6 weeks, up to 5 weeks, at least 4 weeks, at least 3 weeks, at least 2 weeks, or up to least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days or greater at a temperature between about 2°C to 8°C. In yet another embodiment, lysed tumor cells may be stored up to about 1 to 7 days , at least 2 to 6 days, at least 3 to 5 days, at least 3 to 4 days or greater at least about 2°C to 8°C. In one embodiment of the present disclosure, lysed tumor cells may be immediately stored at least about -50°C to -90°C, at least about -60°C to - 85°C, at least about -75°C to -85, or at least about -80°C. In another embodiment, lysed tumor cells may be stored up to least about 1 month, at least about 6 months, at least about 1 year, at least about 2 years, at least about 3 years, at least about 4 years, at least about 5 years or greater at least about -50°C to -90°C.
(iv) Combining deglycosylated tumor cell lysate with an adjuvant system to form a vaccine
[0038] A method of the present disclosure also comprises combining deglycosylated tumor cell lysate with an adjuvant system to form a vaccine. As described herein, an "adjuvant system" is at least one adjuvant, or at least one immunomodulator, or a combination of adjuvants and immunomodulators.
[0039] "Adjuvants" as used herein are agents that enhance the immune response of an antigen. In one embodiment, one or more adjuvants may be a particulate adjuvant. In another embodiment, one or more adjuvants may be an emulsion. In some embodiments, one or more adjuvants may be a water-in-oil emulsion, oil-in-water emulsion, water-in-oil-in-water emulsion. The emulsion can be based in particular on light liquid paraffin oil (European Pharmacopea type); isoprenoid oil such as squalane or squalene oil resulting from the oligomerization of alkenes, in particular of isobutene or decene; esters of acids or of alcohols containing a linear alkyl group, more particularly plant oils, ethyl oleate, propylene glycol di-(caprylate/caprate), glyceryl tri-(caprylate/caprate) or propylene glycol dioleate; esters of branched fatty acids or alcohols, in particular isostearic acid esters. The oil is used in combination with emulsifiers to form the emulsion. The emulsifiers are preferably nonionic surfactants, in particular esters of sorbitan, of mannide (e.g. anhydromannitol oleate), of glycol, of polyglycerol, of propylene glycol and of oleic, isostearic, ricinoleic or hydroxystearic acid, which are optionally ethoxylated, and polyoxypropylene-polyoxyethylene copolymer blocks, in particular the Pluronic products, especially L121. See Hunter et al, The Theory and Practical Application of Adjuvants (Ed.Stewart-Tull, D. E. S.). JohnWiley and Sons, NY, pp51-94 (1995) and Todd et al, Vaccine 15:564-570 (1997). In still another embodiment, one or more adjuvants may be a liposome. In yet another embodiment, one or more adjuvants may be a microsphere of biodegradable polymers. In another embodiment, one or more adjuvants may be an immunomodulator. In one embodiment, an adjuvant system of the present disclosure may be any combination of adjuvants and immunomodulators. Non-limiting examples of immunomodulators comprise monophosphoryl lipid A, bark-saponin Quil A, dsRNA analogues, and N-acetyl muramyl-L- alanyl-D-isoglutamine. Further suitable adjuvant systems useful to the present disclosure include, but are not limited to, the RIBI adjuvant system (Ribi Inc.), Block co-polymer (CytRx, Atlanta GA), SAF-M (Chiron, Emeryville CA), AS 15, MF59, Avridine lipid-amine adjuvant, heat-labile enterotoxin from E. coli (recombinant or otherwise), cholera toxin, IMS 1314, GLA-SE, IC31, CAFOl, ISCOMs, or muramyl dipeptide among many others. In certain preferred embodiments, the adjuvant system may be AS01. In another preferred embodiment, the adjuvant system may be AS02. In yet another preferred embodiment, the adjuvant system may be AS03. In an ideal embodiment, the adjuvant system may be AS04.
[0040] A method of this disclosure comprises combining deglycosylated tumor cell lysates with an adjuvant system to form a vaccine. In on embodiment, lysates from about at least 0.5 to 100 million or greater, at least 5 to 80 million or greater, at least 10 to 70 million or greater, at least 15 to 65 million or greater, at least 20 to 60 million or greater, at least 30 to 50 million or greater, at least 40 to 50 million or greater, or at least 45 to 50 million or greater deglycosylated tumor cells may be mixed with an adjuvant system.
[0041] In one embodiment, vaccines may be immediately stored between about 2°C to
8°C, about 3°C to 5°C, about 4°C to 5, or at about 4°C. In another embodiment, vaccines may be stored up to least about 1 day, at least about 1 week, at least about 2 weeks, at least about 1 month, at least about 3 months, at least about 6 months, at least about 1 year or more at a temperature between about 2°C to 8°C. In yet another embodiment, vaccines may be stored up to least about 1 to about 7 days, at least about 1 to about 2 weeks, at least about 2 weeks to about 1 month, at least about 1 month to about 3 months, at least about 3 months to about 6 months, at least about 6 months to about 1 year or more at a temperature of about 2°C to 8°C.
(b) Administering an Adjuvanted, Deglycosylated Autologous Tumor Composition as a Vaccine and as a Treatment
[0042] One embodiment of the present disclosure provides methods of administering an adjuvanted, deglycosylated autologous tumor composition to a patient for treatment of cancer. The method comprises one or more inoculations over an appropriate range of time wherein at least about 5% or greater of tumor growth may be impaired compared to tumor growth in an untreated patient with identical disease condition and predicted outcome.
(i) Delivery of adjuvanted, deglycosylated autologous tumor vaccine and treatment.
[0043] It is appreciated that one skilled in the art would be able to select an appropriate device for adjuvanted, deglycosylated autologous tumor vaccine delivery to the patient for purposes of the present disclosure. Non-limiting examples of a device appropriate for vaccine delivery may be conventional injection, injection with hollow microneedles and/or solid microneedles, electroporation systems, needle-free jet injection, ballistic particle-mediated delivery, and electroporation.
[0044] In an embodiment of the present disclosure, the delivery route may be selected to produce the appropriate immune response. In one embodiment, the delivery route may be subcutaneous. In another embodiment, the delivery route may be intradermal. In yet another embodiment, the delivery route may be transdermal. In still another embodiment, the delivery route may be intramuscular. In an additional embodiment, the delivery route may be intralymphatic. It is appreciated that one skilled in the art would be able to select an appropriate route for vaccine delivery for purposes of the present disclosure.
[0045] In an embodiment of the present disclosure, one dose of adjuvanted, deglycosylated autologous tumor vaccine may be at least about 0.05 ml or greater to at least about 1.0 ml or greater, at least about 0.2 ml or greater to at least about 0.8 ml or greater, at least about 0.4 ml or greater to at least about 0.6 ml or greater. In another embodiment of the present disclosure, one dose of adjuvanted, deglycosylated autologous tumor vaccine may be at least about 0.05 ml or greater, at least about 0.1 ml or greater, at least about 0.2 ml or greater, at least about 0.3 ml or greater, at least about 0.4 ml or greater, at least about 0.5 ml or greater, at least about 0.6 ml or greater, at least about 0.7 ml or greater, at least about 0.8 ml or greater, at least about 0.9 ml or greater, at least about 1.0 ml or greater. In another embodiment of the present disclosure, one dose of adjuvanted, deglycosylated autologous tumor vaccine may be at least about 0.05 ml or greater to at least about 0.1 ml or greater, at least about 0.1 ml or greater to at least about 0.2 ml or greater, at least about 0.2 ml or greater to at least about 0.3 ml or greater, at least about 0.3 ml or greater to at least about 0.4 ml or greater, at least about 0.4 ml or greater to at least about 0.5 ml or greater, at least about 0.5 ml or greater to at least about 0.6 ml or greater, at least about 0.6 ml or greater to at least about 0.7 ml or greater, at least about 0.7 ml or greater to at least about 0.8 ml or greater, at least about 0.8 ml or greater to at least about 0.9 ml or greater, at least about 0.9 ml or greater to at least about 1.0 ml or greater.
[0046] In another embodiment of the present disclosure, one dose of adjuvanted, deglycosylated autologous tumor vaccine may contain lysate in amounts as described above, or from at least about 5 to 60 million or more, about at least about 20 to 50 million or more, about at least about 40 to 50 million or more, or about at least about 45 to 50 million or more deglycosylated tumor cells. In another embodiment, one dose of tumor vaccine may contain
lysate from an amount of deglycosylated tumor cells as described above, or at least about 5 million or more, at least about 10 million or more, at least about 15 million or more, at least about 20 million or more, at least about 25 million or more, at least about 30 million or more, at least about 35 million or more, at least about 40 million or more, at least about 45 million or more, at least about 50 million or more, at least about 55 million or more, at least about 60 million or more deglycosylated tumor cells. In another embodiment, one dose of tumor vaccine may contain lysate from an amount of tumor cells as described above, or at least about 5 million or more to least about 10 million or more, at least about 10 million or more to least about 10 million or more, at least about 15 million or more to least about 20 million or more, at least about 20 million or more to least about 25 million or more, at least about 25 million or more to at least about 30 million or more, at least about 30 million or more to at least about 35 million or more, at least about 35 million or more to at least about 40 million or more, at least about 40 million or more to at least about 45 million or more, at least about 45 million or more to at least about 50 million or more, at least about 50 million or more to at least about 55 million or more, at least about 55 million or more to at least about 60 million or more deglycosylated tumor cells.
[0047] In another embodiment, a patient may be inoculated with a dose of the adjuvanted, deglycosylated autologous tumor vaccine once or multiple times. In another embodiment, inoculation of the patient with a dose of the tumor vaccine may occur multiple times until desired results are observed. It is appreciated that one skilled in the art would be able to select an appropriate number of inoculations to achieve the desired response for purposes of the present disclosure. In preferred embodiments, inoculation of the patient with a dose of the adjuvanted, deglycosylated autologous tumor vaccine may occur once, up to two times, up to three times, up to four times, or up to five times. One preferred dose regimen comprises four inoculations.
[0048] In one embodiment of the present disclosure, a patient may be inoculated with a dose of the adjuvanted, deglycosylated autologous tumor vaccine multiple times at irregular intervals. In another embodiment, a patient may be inoculated with a dose of the tumor vaccine multiple times at regular intervals. In another embodiment, a patient may be inoculated with a dose of the tumor vaccine multiple times at about at least 1-week or greater, at least 2-week or greater, at least 3 -week or greater, at least 4-week or greater, at least 5 -week or greater, at least 6-
week or greater intervals. In another embodiment, a patient may be inoculated with a dose of the tumor vaccine multiple times at about at least 1-week or greater, at least 2-week or greater to at least 3 -week or greater, at least 3 -week or greater to at least 4-week or greater, at least 4-week or greater to at least 5 -week or greater, at least 5 -week or greater to at least 6-week or greater intervals. It is appreciated that one skilled in the art would be able to select an appropriate interval of inoculation regimen to achieve the desired response for purposes of the present disclosure.
[0049] In another embodiment of the present disclosure, one or more doses of the adjuvanted, deglycosylated autologous tumor vaccine may be administered as a booster vaccine following initial treatment regimen. In one embodiment, one or more doses of the tumor vaccine may be administered for the lifetime of the patient. In one embodiment, a dose of the tumor vaccine may be administered as a booster vaccine at least every 3 months or more, at least every 6 months or more, at least every year or more, at least every 2 years or more, at least every 3 years or more following initial treatment regimen. It is appreciated that one skilled in the art would be able to select an appropriate interval of booster inoculation regimen to achieve the desired response for purposes of the present disclosure.
(ii) Combination therapies involving adjuvanted, deglycosylated autologous tumor vaccine and treatment.
[0050] Another embodiment of the present disclosure may be to combine the adjuvanted, deglycosylated autologous tumor vaccine and treatment prepared as described above with one or more additional therapies that are appropriate for cancer treatment. In one embodiment, the adjuvanted, deglycosylated autologous tumor vaccine, containing complete tumor cell lysate, may be combined with another vaccine containing one or more tumor antigens. In another embodiment, the adjuvanted, deglycosylated autologous tumor vaccine, containing complete tumor cell lysate, may be combined with another vaccine containing one or more tumor growth factor receptors. In other embodiments, implementation of an adjuvanted, deglycosylated autologous tumor vaccine and treatment may be combined with standard-of-care cancer therapies. As used herein, "standard-of-care cancer therapies" entail tone or more treatments accepted by medical experts as a proper treatment for a certain type of disease and that is widely
used by healthcare professionals. These standard of care cancer therapies include chemotherapy as well as radiation therapy. It is appreciated that one skilled in the art would be able to select one or more appropriate standard-of-care cancer therapies to use in combination with the tumor vaccine described in the present disclosure for the desired outcome.
(iii) Disease outcomes following inoculation with an adjuvanted, deglycosylated autologous tumor vaccine and treatment.
[0051] The method of the present disclosure comprises one or more inoculations over an appropriate range of time wherein tumor growth may be impaired compared to tumor growth in an untreated patient with identical disease condition and predicted outcome. In one embodiment, tumor growth may be stopped following treatment with the tumor vaccine described herein. In other embodiments, tumor growth may be impaired at least about 5% or greater to at least about 100%, at least about 10% or greater to at least about 95% or greater, at least about 20% or greater to at least about 80% or greater, at least about 40% or greater to at least about 60% or greater compared to an untreated patient with identical disease condition and predicted outcome. In other words, tumors in patients treated using the methods and compositions of the disclosure have tumors that grow at least 5% less (or more as described above) when compared to an untreated patient with identical disease condition and predicted outcome. In some embodiments, tumor growth may be impaired at least about 5% or greater, at least about 10% or greater, at least about 15% or greater, at least about 20% or greater, at least about 25% or greater, at least about 30% or greater, at least about 35% or greater, at least about 40% or greater, at least about 45%) or greater, at least about 50% or greater, at least about 55% or greater, at least about 60% or greater, at least about 65% or greater, at least about 70% or greater, at least about 75% or greater, at least about 80% or greater, at least about 85% or greater, at least about 90% or greater, at least about 95% or greater, at least about 100% compared to an untreated patient with identical disease condition and predicted outcome. In additional embodiments, tumor growth may be impaired at least about 5% or greater to at least about 10% or greater, at least about 10% or greater to at least about 15% or greater, at least about 15% or greater to at least about 20% or greater, at least about 20% or greater to at least about 25% or greater, at least about 25% or greater to at least about 30% or greater, at least about 30% or greater to at least about 35% or
greater, at least about 35% or greater to at least about 40% or greater, at least about 40% or greater to at least about 45% or greater, at least about 45% or greater to at least about 50% or greater, at least about 50% or greater to at least about 55% or greater, at least about 55% or greater to at least about 60% or greater, at least about 60% or greater to at least about 65% or greater, at least about 65% or greater to at least about 70% or greater, at least about 70% or greater to at least about 75% or greater, at least about 75% or greater to at least about 80% or greater, at least about 80% or greater to at least about 85% or greater, at least about 85% or greater to at least about 90% or greater, at least about 90% or greater to at least about 95% or greater, at least about 95% or greater to at least about 100% compared to an untreated patient with identical disease condition and predicted outcome. In some forms, treatment of tumors results in a shrinking of a tumor in comparison to the starting size of the tumor. This shrinking is at least about 5% or greater to at least about 10% or greater, at least about 10% or greater to at least about 15% or greater, at least about 15% or greater to at least about 20% or greater, at least about 20% or greater to at least about 25% or greater, at least about 25% or greater to at least about 30% or greater, at least about 30% or greater to at least about 35% or greater, at least about 35% or greater to at least about 40% or greater, at least about 40% or greater to at least about 45% or greater, at least about 45% or greater to at least about 50% or greater, at least about 50%) or greater to at least about 55% or greater, at least about 55% or greater to at least about 60%) or greater, at least about 60% or greater to at least about 65% or greater, at least about 65%) or greater to at least about 70% or greater, at least about 70% or greater to at least about 75%) or greater, at least about 75% or greater to at least about 80% or greater, at least about 80%) or greater to at least about 85% or greater, at least about 85% or greater to at least about 90%) or greater, at least about 90% or greater to at least about 95% or greater, at least about 95%) or greater to at least about 100% (meaning that the tumor is completely gone after treatment) compared to the starting size of the tumor.
[0052] The method of the present disclosure comprises one or more inoculations over an appropriate range of time wherein the presence of tumor markers is lower compared to the presence of tumor markers in an untreated patient with identical disease condition and predicted outcome. As used herein "tumor markers" are defined as substances produced by cancer or by other cells of the body in response to cancerous conditions. Non-limiting examples of tumor
markers include alpha-fetoprotein, beta-2-microglobulin, beta-human chorionic gonadotropin, BCR-ABL fusion gene, CA19-9, CD20, HE4, lactate dehydrogenase, prostate-specific antigen, and various others. In one embodiment of the present disclosure, the presence of tumor markers may be ablated following treatment with the tumor vaccine described herein. In other embodiments, the presence of tumor markers may be decreased at least about 5% or greater to at least about 100%, at least about 10% or greater to at least about 95% or greater, at least about 20%) or greater to at least about 80%> or greater, at least about 40% or greater to at least about 60%) or greater compared to an untreated patient with identical disease condition and predicted outcome. In some embodiments, the presence of tumor markers may be decreased at least about 5%) or greater, at least about 10%> or greater, at least about 15%> or greater, at least about 20% or greater, at least about 25% or greater, at least about 30% or greater, at least about 35% or greater, at least about 40% or greater, at least about 45% or greater, at least about 50% or greater, at least about 55% or greater, at least about 60% or greater, at least about 65% or greater, at least about 70% or greater, at least about 75% or greater, at least about 80% or greater, at least about 85% or greater, at least about 90% or greater, at least about 95% or greater, at least about 100% compared to an untreated patient with identical disease condition and predicted outcome. In additional embodiments, the presence of tumor markers may be decreased at least about 5% or greater to at least about 10% or greater, at least about 10% or greater to at least about 15% or greater, at least about 15% or greater to at least about 20% or greater, at least about 20% or greater to at least about 25% or greater, at least about 25% or greater to at least about 30% or greater, at least about 30% or greater to at least about 35% or greater, at least about 35% or greater to at least about 40% or greater, at least about 40% or greater to at least about 45% or greater, at least about 45% or greater to at least about 50% or greater, at least about 50% or greater to at least about 55% or greater, at least about 55% or greater to at least about 60% or greater, at least about 60% or greater to at least about 65% or greater, at least about 65% or greater to at least about 70% or greater, at least about 70% or greater to at least about 75% or greater, at least about 75% or greater to at least about 80% or greater, at least about 80% or greater to at least about 85% or greater, at least about 85% or greater to at least about 90% or greater, at least about 90% or greater to at least about 95% or
greater, at least about 95% or greater to at least about 100% compared to an untreated patient with identical disease condition and predicted outcome.
[0053] The method of the present disclosure comprises one or more inoculations over an appropriate range of time wherein the cancer life expectancy may be improved compared to the cancer life expectancy of an untreated patient with identical disease condition and predicted outcome. As used herein, "cancer life expectancy" is defined as the time at which 50 percent of patients are alive and 50 percent have passed away. In one embodiment of the present disclosure, cancer life expectancy may be indefinite following treatment with the tumor vaccine described herein. In other embodiments, cancer life expectancy may be increased at least about 5%) or greater to at least about 100%, at least about 10% or greater to at least about 95% or greater, at least about 20% or greater to at least about 80% or greater, at least about 40% or greater to at least about 60% or greater compared to an untreated patient with identical disease condition and predicted outcome. In some embodiments, cancer life expectancy may be increased at least about 5% or greater, at least about 10% or greater, at least about 15% or greater, at least about 20% or greater, at least about 25% or greater, at least about 30% or greater, at least about 35% or greater, at least about 40% or greater, at least about 45% or greater, at least about 50% or greater, at least about 55% or greater, at least about 60% or greater, at least about 65% or greater, at least about 70% or greater, at least about 75% or greater, at least about 80% or greater, at least about 85% or greater, at least about 90% or greater, at least about 95% or greater, at least about 100% compared to an untreated patient with identical disease condition and predicted outcome. In additional embodiments, cancer life expectancy may be increased at least about 5% or greater to at least about 10% or greater, at least about 10% or greater to at least about 15% or greater, at least about 15% or greater to at least about 20% or greater, at least about 20% or greater to at least about 25% or greater, at least about 25% or greater to at least about 30% or greater, at least about 30% or greater to at least about 35% or greater, at least about 35% or greater to at least about 40% or greater, at least about 40%) or greater to at least about 45% or greater, at least about 45% or greater to at least about 50%) or greater, at least about 50% or greater to at least about 55% or greater, at least about 55%) or greater to at least about 60% or greater, at least about 60% or greater to at least about 65%) or greater, at least about 65% or greater to at least about 70% or greater, at least
about 70% or greater to at least about 75% or greater, at least about 75% or greater to at least about 80%) or greater, at least about 80%> or greater to at least about 85%> or greater, at least about 85%) or greater to at least about 90% or greater, at least about 90% or greater to at least about 95% or greater, at least about 95% or greater to at least about 100% compared to an untreated patient with identical disease condition and predicted outcome.
II. An Adjuvanted, Deglycosylated Autologous Tumor Vaccine and Treatment
[0054] One aspect of the present disclosure provides an adjuvanted, deglycosylated autologous tumor vaccine and treatment. The vaccine may be derived from a cancerous lesion harvested from a patient. In an embodiment of the present disclosure, the cancer may be a primary cancer, a metastases, or primary cancer and metastases. In one embodiment, the cancer may be a solid cancer. In another embodiment, the cancer may be a liquid cancer. In some embodiments, the tumor grade of the harvested tissue may be between 1 and 4, may be 1, may be 2, may be 3, or may be 4. Generally speaking, methods of harvesting tumors from patients are known in the art and it is appreciated that one skilled in the art would be able to select one or more appropriate methods to harvest cancerous tissue or cells as described in the present disclosure.
[0055] In one embodiment, a harvested tumor cell source to generate the tumor vaccine is large enough to obtain a sample from which the composition can be made. In some embodiments, the tumor cell source may be between about 0.2 cm3 to at least about 20 cm3 or greater, at least 2 cm3 to at least about 18 cm3 or greater, at least 3 cm3 to at least about 15 cm3 or greater, at least 4 cm3 to at least about 12 cm3 or greater, at least 5 cm3 to at least about 10 cm3 or greater, or at least 6 cm3 to at least about 8 cm3 or greater. A harvested tumor cell source may be at least about 1 cm3 or greater, at least about 2 cm3 or greater, at least about 3 cm3 or greater, at least about 4 cm3 or greater, at least about 5 cm3 or greater, at least about 6 cm3 or greater, at least about 7 cm3 or greater, at least about 8 cm3 or greater, at least about 9 cm3 or greater, at least about 10 cm3 or greater, at least about 1 1 cm3 or greater, at least about 12 cm3 or greater, at least about 13 cm3 or greater, at least about 14 cm3 or greater, at least about 15 cm3 or greater, at least about 16 cm3 or greater, at least about 17 cm3 or greater, at least about 18 cm3 or greater, at
least about 19 cm3 or greater, or at least about 20 cm3 or greater. In certain embodiments, a harvested tumor cell source may be at least about 0.2 cm3 to about 0.3 cm3 or greater, at least about 0.3 cm3 to about 0.4 cm3 or greater, at least about 0.4 cm3 to about 0.5 cm3 or greater, at least about 0.5 cm3 to about 1 cm3 or greater, at least about 1 cm3 to about 2 cm3 or greater, at least about 2 cm3 to about 3 cm3 or greater, at least about 3 cm3 to about 4 cm3 or greater, at least about 4 cm3 to about 5 cm3 or greater, at least about 5 cm3 to about 6 cm3 or greater, at least about 6 cm3 to about 7 cm3 or greater, at least about 7 cm3 to about 8 cm3 or greater, at least about 8 cm3 to about 9 cm3 or greater, at least about 9 cm3 to about 10 cm3 or greater, at least about 10 cm3 to about 11 cm3 or greater, at least about 11 cm3 to about 12 cm3 or greater, at least about 12 cm3 to about 13 cm3 or greater, at least about 13 cm3 to about 14 cm3 or greater, at least about 14 cm3 to about 15 cm3 or greater, at least about 15 cm3 to about 16 cm3 or greater, at least about 16 cm 3 to about 17 cm 3 or greater, at least about 17 cm 3 to about 18 cm 3 or greater, 18 cm 3 to about 19 cm3 or greater, or at least about 19 cm3 to about 20 cm3 or greater.
[0056] In one embodiment, a harvested tumor cell source may yield a number of cells as described above or between at least about 0.5 million cells to at least about 100 million cells or greater, at least about 3 million cells to at least about 60 million cells or greater, at least about 5 million cells to at least about 60 million cells or greater, at least about 10 million cells to at least about 60 million cells or greater, at least about 15 million cells to at least about 60 million cells or greater, at least about 20 million cells to at least about 60 million cells or greater, at least about 25 million cells to at least about 50 million cells or greater, at least about 30 million cells to at least about 40 million cells or greater, or at least about 45 million cells to at least about 45 million cells or greater. In one embodiment, tumor cells may be expanded in culture to obtain at least about 0.5 million cells, at least about 1 million cells, at least about 5 million cells, at least about 7 million cells, at least about 10 million cells, at least about 15 million cells, at least about 20 million cells, at least about 25 million cells, at least about 30 million cells, 35 million cells, at least about 40 million cells, at least about 45 million cells, at least about 50 million cells, at least about 55 million cells, at least about 60 million cells, or greater. In another embodiment, tumor cells may be expanded in culture to obtain at least about 0.5 million cells to at least about 60 million cells, at least about 5 million cells to at least about 60 million cells, at least about 7 million cells to at least about 60 million cells, at least about 10 million cells to at least about 15
million cells, at least about 15 million cells to at least about 20 million cells, at least about 20 million cells to at least about 25 million cells, at least about 25 million cells to at least about 30 million cells, at least about 30 million cells to at least about 35 million cells, 35 million cells to at least about 40 million cells, at least about 40 million cells to at least about 45 million cells, at least about 45 million cells to at least about 50 million cells, at least about 50 million cells to at least about 55 million cells, at least about 55 million cells to at least about 60 million cells.
[0057] An adjuvanted, deglycosylated autologous tumor vaccine and treatment may be composed of tumor cells wherein a majority of tumor cell membrane may be deglycosylated. In preferred forms, at least about 55% or more of the tumor cell membrane may be deglycosylated. More preferably, at least about 65% or more of the tumor cell membrane may be deglycosylated. Still more preferably, at least about 75% or more of the tumor cell membrane may be deglycosylated. Still more preferably, at least about 85% or more of the tumor cell membrane may be deglycosylated. Ideally, at least about 95% or more of the tumor cell membrane may be deglycosylated. In one embodiment, at least about 55% to 95% or greater, at least about 65% to 95% or greater, at least about 75% to 95% or greater, at least about 85% to 95% or greater, or at least about 90% to 95% or greater of tumor cell membrane may be deglycosylated.
[0058] An adjuvanted, deglycosylated autologous tumor vaccine and treatment may be composed of deglycosylated tumor cell lysate that may be stored for vaccine production. It is appreciated that one skilled in the art would be able to select an appropriate method for lysing tumor cells and for storing tumor cells for purposes of the present disclosure. Lysed tumor cells may be immediately stored as described above or at least about 2°C to 8°C, at least about 3°C to 5°C, at least about 4°C to 5, or at least about 4°C. In another embodiment, vaccines may be stored up to least about 1 day, at least about 1 week, at least about 2 weeks, at least about 1 month, at least about 3 months, at least about 6 months, at least about 1 year or more at a temperature between about 2°C to 8°C. In yet another embodiment, vaccines may be stored up to least about 1 to about 7 days, at least about 1 to about 2 weeks, at least about 2 weeks to about 1 month, at least about 1 month to about 3 months, at least about 3 months to about 6 months, at least about 6 months to about 1 year or more at a temperature of about 2°C to 8°C. In one embodiment of the present disclosure, lysed tumor cells may be immediately stored at least about
-50°C to -90°C, at least about -60°C to -85°C, at least about -75°C to -85, or at least about -80°C. In another embodiment, lysed tumor cells may be stored up to least about 1 month, at least about 6 months, at least about 1 year, at least about 2 years, at least about 3 years, at least about 4 years, at least about 5 years or greater at least about -50°C to -90°C.
[0059] An adjuvanted, deglycosylated autologous tumor vaccine and treatment may be composed of deglycosylated tumor cell lysate combined with an adjuvant system. Suitable adjuvant systems useful to the present disclosure are known in the art and are described above. In preferred embodiments, the adjuvant system may be AS01, AS02, and/or AS03. In an ideal embodiment, the adjuvant system may be AS04.
[0060] In one embodiment, an adjuvanted, deglycosylated autologous tumor vaccine may be immediately stored as described above or at least about 2°C to 8°C, at least about 3°C to 5°C, at least about 4°C to 5, or at least about 4°C. In another embodiment, vaccines may be stored up to least about 1 day, at least about 1 week, at least about 2 weeks, at least about 1 month, at least about 3 months, at least about 6 months, at least about 1 year or more at a temperature between about 2°C to 8°C. In yet another embodiment, vaccines may be stored up to least about 1 to about 7 days, at least about 1 to about 2 weeks, at least about 2 weeks to about 1 month, at least about 1 month to about 3 months, at least about 3 months to about 6 months, at least about 6 months to about 1 year or more at a temperature of about 2°C to 8°C.
[0061] It is appreciated that one skilled in the art would be able to select an appropriate device for adjuvanted, deglycosylated autologous tumor vaccine delivery to the patient for purposes of the present disclosure. In an embodiment of the present disclosure, the delivery route may be selected to produce the appropriate immune response. In one embodiment, the delivery route may be subcutaneous. In another embodiment, the delivery route may be intradermal. In yet another embodiment, the delivery route may be transdermal. In still another embodiment, the delivery route may be intramuscular. In an additional embodiment, the delivery route may be intralymphatic. It is appreciated that one skilled in the art would be able to select an appropriate route for vaccine delivery for purposes of the present disclosure.
[0062] One dose of an adjuvanted, deglycosylated autologous tumor vaccine and treatment may be composed of a volume as described above or of at least about 0.05 ml or greater to at
least about 1.0 ml or greater, at least about 0.2 ml or greater to at least about 0.8 ml or greater, at least about 0.4 ml or greater to at least about 0.6 ml or greater. In another embodiment of the present disclosure, one dose of adjuvanted, deglycosylated autologous tumor vaccine may be at least about 0.05 ml or greater, at least about 0.1 ml or greater, at least about 0.2 ml or greater, at least about 0.3 ml or greater, at least about 0.4 ml or greater, at least about 0.5 ml or greater, at least about 0.6 ml or greater, at least about 0.7 ml or greater, at least about 0.8 ml or greater, at least about 0.9 ml or greater, at least about 1.0 ml or greater. In another embodiment of the present disclosure, one dose of adjuvanted, deglycosylated autologous tumor vaccine may be at least about 0.05 ml or greater to at least about 0.1 ml or greater, at least about 0.1 ml or greater to at least about 0.2 ml or greater, at least about 0.2 ml or greater to at least about 0.3 ml or greater, at least about 0.3 ml or greater to at least about 0.4 ml or greater, at least about 0.4 ml or greater to at least about 0.5 ml or greater, at least about 0.5 ml or greater to at least about 0.6 ml or greater, at least about 0.6 ml or greater to at least about 0.7 ml or greater, at least about 0.7 ml or greater to at least about 0.8 ml or greater, at least about 0.8 ml or greater to at least about 0.9 ml or greater, at least about 0.9 ml or greater to at least about 1.0 ml or greater.
[0063] One dose of an adjuvanted, deglycosylated autologous tumor vaccine and treatment may be composed of lysate as described above, or from at least about 0.5 to 60 million or more, about at least about 20 to 50 million or more, about at least about 40 to 50 million or more, or about at least about 45 to 50 million or more deglycosylated tumor cells. In another embodiment, one dose of tumor vaccine may contain lysate from at least about 0.5 million or more, at least about 1 million or more, at least about 5 million or more, at least about 10 million or more, at least about 15 million or more, at least about 20 million or more, at least about 25 million or more, at least about 30 million or more, at least about 35 million or more, at least about 40 million or more, at least about 45 million or more, at least about 50 million or more, at least about 55 million or more, at least about 60 million or more deglycosylated tumor cells. In another embodiment, one dose of tumor vaccine may contain lysate from at least about 0.5 million or more to least about 1 million or more, at least about 1 million or more to least about 5 million or more, at least about 5 million or more to least about 10 million or more, at least about 10 million or more to least about 15 million or more, at least about 15 million or more to least about 20 million or more, at least about 20 million or more to least about 25 million or more, at
least about 25 million or more to at least about 30 million or more, at least about 30 million or more to at least about 35 million or more, at least about 35 million or more to at least about 40 million or more, at least about 40 million or more to at least about 45 million or more, at least about 45 million or more to at least about 50 million or more, at least about 50 million or more to at least about 55 million or more, at least about 55 million or more to at least about 60 million or more deglycosylated tumor cells.
[0064] In another embodiment of the present disclosure, a treatment regimen composed of an adjuvanted, deglycosylated autologous tumor vaccine and treatment may include inoculation of the patient once or multiple times. In another embodiment, inoculation of the patient with a dose of the tumor vaccine may occur multiple times until desired results are observed. It is appreciated that one skilled in the art would be able to select an appropriate number of inoculations to achieve the desired response for purposes of the present disclosure. In preferred embodiments, inoculation of the patient with a dose of the adjuvanted, deglycosylated autologous tumor vaccine may occur once, up to two times, up to three times, up to four times, up to five times. In another embodiment of the present disclosure, a patient may be inoculated with a dose of the adjuvanted, deglycosylated autologous tumor vaccine multiple times at irregular intervals. In yet another embodiment, a patient may be inoculated with a dose of the tumor vaccine multiple times at regular intervals. In still another embodiment, a patient may be inoculated with a dose of the tumor vaccine multiple times at about at least 2-week or greater, at least 3 -week or greater, at least 4-week or greater, at least 5 -week or greater, at least 6-week or greater intervals. In another embodiment, a patient may be inoculated with a dose of the tumor vaccine multiple times at about at least 2-week or greater to at least 3 -week or greater, at least 3- week or greater to at least 4-week or greater, at least 4-week or greater to at least 5 -week or greater, at least 5-week or greater to at least 6-week or greater intervals. It is appreciated that one skilled in the art would be able to select an appropriate interval of inoculation regimen to achieve the desired response for purposes of the present disclosure.
[0065] In another embodiment of the present disclosure, a booster vaccine composed of an adjuvanted, deglycosylated autologous tumor vaccine may be administered following initial treatment regimen. In one embodiment, one or more doses of the tumor vaccine may be
administered for the lifetime of the patient. In one embodiment, a dose of the tumor vaccine may be administered as a booster vaccine at least every 3 months or more, at least every 6 months or more, at least every year or more, at least every 2 years or more, at least every 3 years or more following initial treatment regimen. It is appreciated that one skilled in the art would be able to select an appropriate interval of booster inoculation regimen to achieve the desired response for purposes of the present disclosure.
[0066] In the present disclosure, an adjuvanted, deglycosylated autologous tumor vaccine and treatment may impair growth of cancerous tumors in an inoculated patient compared to an untreated patient with identical disease condition and predicted outcome. In one embodiment, tumor growth may be stopped following treatment with the tumor vaccine described herein. In other embodiments, tumor growth may be impaired at least about 5% or greater to at least about 100%, at least about 10% or greater to at least about 95% or greater, at least about 20% or greater to at least about 80% or greater, at least about 40% or greater to at least about 60% or greater compared to an untreated patient with identical disease condition and predicted outcome. "Impaired tumor growth" refers to a decrease in growth of a tumor in comparison to tumor growth in an untreated patient with identical disease condition and predicted outcome. In some embodiments, tumor growth may be impaired, at least about 5% or greater, at least about 10% or greater, at least about 15% or greater, at least about 20% or greater, at least about 25% or greater, at least about 30% or greater, at least about 35% or greater, at least about 40% or greater, at least about 45% or greater, at least about 50% or greater, at least about 55% or greater, at least about 60% or greater, at least about 65% or greater, at least about 70% or greater, at least about 75% or greater, at least about 80% or greater, at least about 85% or greater, at least about 90% or greater, at least about 95% or greater, at least about 100% compared to an untreated patient with identical disease condition and predicted outcome. In additional embodiments, tumor growth may be impaired at least about 5% or greater to at least about 10%) or greater, at least about 10% or greater to at least about 15% or greater, at least about 15%) or greater to at least about 20% or greater, at least about 20% or greater to at least about 25%) or greater, at least about 25% or greater to at least about 30% or greater, at least about 30% or greater to at least about 35% or greater, at least about 35% or greater to at least about 40%) or greater, at least about 40% or greater to at least about 45% or greater, at least about
45% or greater to at least about 50% or greater, at least about 50% or greater to at least about 55%) or greater, at least about 55% or greater to at least about 60% or greater, at least about 60% or greater to at least about 65% or greater, at least about 65% or greater to at least about 70% or greater, at least about 70% or greater to at least about 75% or greater, at least about 75% or greater to at least about 80% or greater, at least about 80% or greater to at least about 85% or greater, at least about 85% or greater to at least about 90% or greater, at least about 90% or greater to at least about 95% or greater, at least about 95% or greater to at least about 100% compared to an untreated patient with identical disease condition and predicted outcome. In some forms, treatment of tumors results in a shrinking of a tumor in comparison to the starting size of the tumor. This shrinking is at least about 5% or greater to at least about 10% or greater, at least about 10% or greater to at least about 15% or greater, at least about 15% or greater to at least about 20% or greater, at least about 20% or greater to at least about 25% or greater, at least about 25% or greater to at least about 30% or greater, at least about 30% or greater to at least about 35% or greater, at least about 35% or greater to at least about 40% or greater, at least about 40%) or greater to at least about 45% or greater, at least about 45% or greater to at least about 50%) or greater, at least about 50% or greater to at least about 55% or greater, at least about 55%) or greater to at least about 60% or greater, at least about 60% or greater to at least about 65%) or greater, at least about 65% or greater to at least about 70% or greater, at least about 70%) or greater to at least about 75% or greater, at least about 75% or greater to at least about 80%) or greater, at least about 80% or greater to at least about 85% or greater, at least about 85%) or greater to at least about 90% or greater, at least about 90% or greater to at least about 95%) or greater, at least about 95% or greater to at least about 100% (meaning that the tumor is completely gone after treatment) compared to the starting size of the tumor.
[0067] Also in the present disclosure, an adjuvanted, deglycosylated autologous tumor vaccine and treatment may reduce the presence of one or more tumor markers in an inoculated patient compared to an untreated patient with identical disease condition and predicted outcome. In one embodiment of the present disclosure, the presence of tumor markers may be ablated following treatment with the tumor vaccine described herein. In other embodiments, the presence of tumor markers may be decreased as described above or at least about 5% or greater to at least about 100%, at least about 10% or greater to at least about 95% or greater, at least
about 20% or greater to at least about 80%> or greater, at least about 40% or greater to at least about 60%) or greater compared to an untreated patient with identical disease condition and predicted outcome. In some embodiments, the presence of tumor markers may be decreased at least about 5% or greater, at least about 10%> or greater, at least about 15%> or greater, at least about 20%) or greater, at least about 25% or greater, at least about 30%> or greater, at least about 35%) or greater, at least about 40% or greater, at least about 45% or greater, at least about 50% or greater, at least about 55% or greater, at least about 60% or greater, at least about 65% or greater, at least about 70% or greater, at least about 75% or greater, at least about 80% or greater, at least about 85% or greater, at least about 90% or greater, at least about 95% or greater, at least about 100% compared to an untreated patient with identical disease condition and predicted outcome. In additional embodiments, the presence of tumor markers may be decreased at least about 5% or greater to at least about 10% or greater, at least about 10% or greater to at least about 15% or greater, at least about 15% or greater to at least about 20% or greater, at least about 20% or greater to at least about 25% or greater, at least about 25% or greater to at least about 30% or greater, at least about 30% or greater to at least about 35% or greater, at least about 35% or greater to at least about 40% or greater, at least about 40% or greater to at least about 45% or greater, at least about 45% or greater to at least about 50% or greater, at least about 50% or greater to at least about 55% or greater, at least about 55% or greater to at least about 60% or greater, at least about 60% or greater to at least about 65% or greater, at least about 65% or greater to at least about 70% or greater, at least about 70% or greater to at least about 75% or greater, at least about 75% or greater to at least about 80% or greater, at least about 80% or greater to at least about 85% or greater, at least about 85% or greater to at least about 90% or greater, at least about 90% or greater to at least about 95% or greater, at least about 95% or greater to at least about 100% compared to an untreated patient with identical disease condition and predicted outcome.
[0068] Within the present disclosure, an adjuvanted, deglycosylated autologous tumor vaccine and treatment may improve the cancer life expectancy of an inoculated patient compared to that of an untreated patient with identical disease condition and predicted outcome. In one embodiment of the present disclosure, cancer life expectancy may be indefinite following treatment with the tumor vaccine described herein. In other embodiments, cancer life
expectancy may be increased as described above or at least about 5% or greater to at least about 100%, at least about 10%> or greater to at least about 95% or greater, at least about 20% or greater to at least about 80%> or greater, at least about 40% or greater to at least about 60%> or greater compared to an untreated patient with identical disease condition and predicted outcome. In some embodiments, cancer life expectancy may be increased at least about 5% or greater, at least about 10% or greater, at least about 15% or greater, at least about 20% or greater, at least about 25%) or greater, at least about 30% or greater, at least about 35% or greater, at least about 40%) or greater, at least about 45% or greater, at least about 50% or greater, at least about 55% or greater, at least about 60% or greater, at least about 65% or greater, at least about 70% or greater, at least about 75% or greater, at least about 80% or greater, at least about 85% or greater, at least about 90% or greater, at least about 95% or greater, at least about 100% compared to an untreated patient with identical disease condition and predicted outcome. In additional embodiments, cancer life expectancy may be increased at least about 5% or greater to at least about 10% or greater, at least about 10% or greater to at least about 15% or greater, at least about 15% or greater to at least about 20% or greater, at least about 20% or greater to at least about 25% or greater, at least about 25% or greater to at least about 30% or greater, at least about 30% or greater to at least about 35% or greater, at least about 35% or greater to at least about 40% or greater, at least about 40% or greater to at least about 45% or greater, at least about 45%) or greater to at least about 50% or greater, at least about 50% or greater to at least about 55%) or greater, at least about 55% or greater to at least about 60% or greater, at least about 60%) or greater to at least about 65% or greater, at least about 65% or greater to at least about 70%) or greater, at least about 70% or greater to at least about 75% or greater, at least about 75%) or greater to at least about 80% or greater, at least about 80% or greater to at least about 85%) or greater, at least about 85% or greater to at least about 90% or greater, at least about 90%) or greater to at least about 95% or greater, at least about 95% or greater to at least about 100%) compared to an untreated patient with identical disease condition and predicted outcome.
III. A Deglycosylated Autologous Tumor Vaccine Composition and Treatment
[0069] In other preferred forms, the composition of the present disclosure can comprise a deglycosylated autologous tumor cells or tumor cell lysate as described above, wherein the tumor cells or tumor cell lysate is combined with at least one additional component selected from the group consisting of pharmaceutically-acceptable carriers, adjuvants, diluents, preservatives, antibiotics, and combinations thereof prior to administration. A "pharmaceutically-acceptable carrier" refers to includes any and all solvents, dispersion media, coatings, stabilizing agents, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, adsorption delaying agents, and the like. Diluents can include water, saline, dextrose, ethanol, glycerol, and the like. Isotonic agents can include sodium chloride, dextrose, mannitol, sorbitol, and lactose, among others. Stabilizers include albumin and alkali salts of ethylendiamintetracetic acid, among others.
[0070] Adjuvants are as described above.
[0071] A "protectant" or "preservative" as used herein, refers to an anti-microbiological active agent, such as for example Neomycin, Amphoteracin B, Gentamycin, Merthiolate, and the like. Of these, Neomycin and/or Amphoteracin B are particularly preferred. In particular adding a protectant is most preferred for the preparation of a multi-dose composition. Those anti- microbiological active agents are added in concentrations effective to prevent the composition of interest from any microbiological contamination or for inhibition of any microbiological growth within the composition of interest.
[0072] Moreover, this method can also comprise the addition of any stabilizing agent, such as for example saccharides, trehalose, mannitol, saccharose and the like, to increase and/or maintain product shelf-life.
[0073] Thus, the composition of the present disclosure can comprise a deglycosylated tumor cell lysate, together with a dispersion media, or a solvent, or a coating, or a stabilizing agent, or a diluent, or a preservative, or an adjuvant, or an antibacterial or antifungal agent, or an isotonic agent, or an adsorption delaying agent, or any combination of the above.
[0074] In additional preferred forms, the composition of the present disclosure can comprise deglycosylated autologous tumor cells or deglycosylated tumor cell lysate derived from allogeneic cancer cells. In one embodiment, allogeneic cancer cells may be sourced from
another member of the same species as the patient. In another embodiment, allogeneic cancer cells may be sourced from another the same tumor type. Non-limiting sources of allogeneic cancer cells comprise of laboratory-grown cancer cell lines and tumor cells isolated from a donor. In certain embodiments, allogeneic tumor cells may be genetically modified.
[0075] The composition of the present disclosure may comprise a deglycosylated tumor vaccine derived from deglycosylated allogeneic cancer cells to be used as a cancer prevention vaccine. As used herein, a "cancer prevention vaccine" is administered to healthy patients to prevent cancers from developing. In one embodiment, the deglycosylated cancer cell cancer prevention vaccine may be derived of cancer cells from multiple cancer types. In another embodiment, the deglycosylated cancer cell cancer prevention vaccine may be derived of cancer cells from one or more cancer types. In yet another embodiment, the deglycosylated cancer cell cancer prevention vaccine may be derived of cancer cells from at least five, at least four, at least three, at least two, at least one cancer types. In one embodiment, the deglycosylated cancer cell cancer prevention vaccine may be administered to the patient multiple times over an appropriate time span to achieve the desired response. In certain embodiments, the deglycosylated cancer cell cancer prevention vaccine may be administered to the patient at least 10 times, at least 9 times, at least 8 times, at least 7 times, at least 6 times, at least 5 times, at least 4 times, at least 3 times, at least 2 times, at least once. In another embodiment, the deglycosylated cancer cell cancer prevention vaccine may be administered to the patient at appropriate time intervals. In certain embodiments, the deglycosylated cancer cell cancer prevention vaccine may be administered to the patient at least every 5 years, at least every 3 years, at least every year, at least every 9 months, at least every 6 months, at least every 3 months, at least every month, at least every 3 weeks, at least every 2 weeks, at least every week, at least every four days, at least every two days, at least every day.
DRAWINGS
[0076] The drawings described herein are for illustration purposes only and are not intended to limit the scope of the present teachings in any way.
[0077] FIG. 1 is an x-ray showing metastatic nodule identified throughout the lung fields.
[0078] FIG. 2 is an x-ray showing the metastatic nodules identified in FIG. 1 had progressed.
[0079] FIG. 3 is an x-ray showing no metastatic disease clearly visible after treatment.
[0080] Corresponding reference numerals indicate corresponding parts throughout the several views of drawings.
DETAILED DESCRIPTION
[0081] The following description is merely exemplary in nature and is in no way intended to limit the present teachings, application, of uses. Throughout this specification, like reference numerals will be used to refer to like elements.
[0082] The disclosure teaches a novel therapeutic vaccine approach that can trigger a therapeutic antitumor response in a cancer patient or a healthy subject. The inventive approach is to selectively eliminate the carbohydrate sequences from tumor cells without affecting the tumor associated protein epitopes. The disclosure further teaches that the evidence that in humans, the expression of Lewisy, SLEX and other carbohydrate sequences increases dramatically on tumor cells near the end stage of cancer, suggests that these TACAs help to make them invulnerable to the immune response. Thus the loss of these TACAs will de-shield these tumor cells from companion dogs, revealing immunogenic molecules that will trigger a therapeutic antitumor response.
[0083] More specifically, the disclosure teaches that first, a suitable method may have to be generated to isolate tumor cells from other normal cells within the tumor. There are numerous ways to perform this type of isolation, which will likely be specific for the type of cancer cells that are targets. Once such tumor cells are isolated, it may be important first to shut down protein synthesis with an active DNA crosslinking agent like mitomycin C. An active inhibitor of glycosylation may also be necessary to globally eliminate the additional of any more glycan sequences. The famous AIDS drug AZT is an excellent inhibitor of glycosylation at a final concentration of about 20 μΜ. These two drugs can be given to the tumor cells, which may be incubated with a variety of different glycosidases (neuraminidase, β-galactosidase, (β-and oc-N- acetylgalactosaminidase, a-fucosidase, a-mannosidase, and endo- -galactosidase). These
enzymes may be able to extensively digest the surface glycans on the tumor cells, enabling immune cell access to tumor associated epitopes that are newly exposed and for which tolerance has not been induced. The digested tumor cells may be collected and screened for the loss of specific glycan epitopes with antibodies and lectins to confirm their removal. Once deglycosylated on is achieved, cells may be injected intramuscularly or into the peritoneal cavity of cancer patients along with alum and monophoryl lipid A adjuvants.
[0084] The inventor has initiated a prospective, single arm efficacy trial of an adjuvanted deglycosylated tumor vaccine in canines. Tumor specimens (about 3 cm3) were collected surgically during treatment of naive dogs that had developed either melanoma or apocrine gland anal sac adenocarcinoma (AGASACA). In some cases, draining lymph nodes were not removed to determine the efficacy of immune activation. Tumor cells were isolated and treated with exoglycosidases and chemical oxidation procedures to remove CFGs. Successful elimination of CFGs was confirmed by lectin binding analysis of the treated cells. The tumor cells were subjected to 5X freeze-thaw cycles to kill them and generate tumor cell lysates. This lysate was mixed with AS04 adjuvant (alum, monophosphoryl lipid A) in physiological saline (0.14 M). This combination is routinely employed in vaccinations against viruses and bacteria in humans. Dogs were inoculated subcutaneously at different sites on their limbs with lysates from 7-10 X 106 cells at 0, 2, 4 and 6 weeks.
[0085] The following examples are included to demonstrate preferred embodiments of the disclosure. It should be appreciated by those of skill in the art that the techniques disclosed in the examples that follow represent techniques discovered by the inventors to function well in the practice of the disclosure, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the disclosure.
EXAMPLE 1. Vaccine immunization therapy on a dog with cancer.
[0086] The mass in the patient dog, a 14 year old neutered male cocker spaniel, was identified in the mouth in addition to multiple metastatic lymph nodes. A 2.5 cm3 metastatic lymph node was surgically removed and confirmed as a melanoma. Initial thoracic radiographs
were unremarkable. The mass was surgically removed again and tumor cells were isolated and expanded in culture using standard methods. Tumor cells were deglycoslated as described herein. Lysates of deglycoslated tumor cells were prepared and mixed with an AS04 adjuvant system for preparation of autologous vaccine. The patient dog was vaccinated with the resulting autologous vaccine four times at 2 week intervals (0, 2, 4, and 6 weeks). Each inoculation was performed intradermally over the right popliteal region. Each dose contained lysates from 7 million deglycoslated tumor cells and 550 mg of AS04 suspended in 0.5 ml of physiological saline.
[0087] Refer to FIG. 1. Radiographs of the thorax on before first surgical intervention revealed the development of metastatic disease in the lung fields.
[0088] Refer to FIG. 2. Radiographs of the thorax on before surgical harvest of the metastatic lymph node revealed progression of metastatic disease.
[0089] Refer to FIG. 3. Radiographs of the thorax after the fourth inoculation revealed resolution of metastatic disease. No other therapy was administered to this dog.
EXAMPLE 2. Preparation of an Adjuvanted, Deglycosylated Autologous Tumor Vaccine from Canine Tumor Cells.
[0090] Melanoma or AGASACA tumors or metastatic nodes (about 3-4 cm3) were surgically excised from the canine patient and placed in a sterile tube containing chilled RPMI 1640 media (Gibco) on ice and immediately transferred to a tissue culture suite. Tumor cells were separated from non-tumor cell types (e.g., blood cells, fibroblasts, supportive cell types) and connective tissues using the Miltenyi Biotec tumor dissociation kit (for human tumor cells) in conjunction with a gentleMACS Dissociator. The resulting dissociated tumor cells were plated out in RPMI 1640 media (Gibco) containing 10% fetal calf serum (Sigma- Aldrich), 100 units of penicillin-streptomycin mixture/ml (Gibco), Glutamax (L-alanyl-L-glutamine; 1 ml/100 ml of media; Gibco) and Fungizone (amphotericin B (1 ml/500 ml)). Tumor cells were allowed to adhere to the plate, while other cells stayed in suspension. After three days, nonadherent contaminating cells were removed, leaving about 500,000-1 million tumor cells/cm3 tumor tissue. These tumor cells were seeded into two T-75 flasks. The tumor cells were expanded in culture until about 35-40 million tumor cells were obtained.
[0091] To deglycosylate the tumor cells, cells were suspended in new media (2 million cells/ml) supplemented with 5 μg/ml tunicamycin (Sigma- Aldrich), 2 mM benzyl 2-acetamido-2- deoxy-a-D-galactopyranoside (Sigma- Aldrich) and D-threo-l-phenyl-2-decanoylamino-3- morpholino-l-propanol (Matreya LLC) to inhibit N-glycosylation, O-glycosylation and glycosphingolipid synthesis, respectively. The media was also supplemented with the following glycosidases: neuraminidase from Clostridium perfringens (New England BioLabs, 100 units/ml), β1-4 galactosidase from Streptococcus pneumoniae (Prozyme, 10 mU/ml) and endo-β- galactosidase (QA-Bio, 30 mU/ml). The tumor cells were incubated for 3 hours, centrifuged (500xg, 10 minutes), and washed with physiological saline (0.85% NaCl). They were then resuspended in 50 mM sodium phosphate buffer (pH 6.0) containing 0.15 M NaCl and freshly prepared 50 mM sodium-m-periodate. The cells were incubated for 1 hour in the dark at 23°C. Periodate oxidation was terminated by the addition of 50 μΐ of ethylene glycol/ml of buffer.
[0092] Deglycosylated tumor cells were next pelleted by centrifugation (500xg, 10 minutes) resuspended in physiologic saline and transferred to a cryovial. The cells were pelleted again by centrifugation. The cells were subjected to five freeze-thaw cycles (-80°C, 37°C) to break the cellular membrane and generate lysates.
[0093] Tumor cell lysates were mixed with 2.2 mg of Adjuvant System 04 (AS04). AS04 is a mixture of Alhydrogel® adjuvant 2% and 220 μg of synthetic monophosphoryl lipid A that induces a transient localized innate immune response that enhances adaptive immunity in humans. The lysate and AS04 were suspended in sterile physiological saline to a final volume of 2.2 ml. This vaccine was immediately refrigerated and stored at 4°C.
EXAMPLE 3. Assessment of an Adjuvanted, Deglycosylated Autologous Tumor Vaccine on Metastatic Progression in Canines.
[0094] Four dogs with naturally-occurring oral melanoma were enrolled into a single-arm trial to assess the efficacy of an adjuvanted, deglycosylated autologous tumor vaccine. To be included in the study, dogs could be of any sex but a minimum weight of 10 kg was required. Dogs in the study had an oral melanoma lesion of at least 2 cm in longest diameter or metastatic lymph nodes that could be surgically resected for vaccine preparation. Dogs could be of any stage of disease progression, but a performance score of 0 or 1 with a minimum estimated life
expectancy of 12 weeks was required for inclusion. Dogs could not be receiving immunosuppressive therapy. Metastatic lesions could not have been treated with radiation therapy. Dogs with melanoma could not have received the ONCEPT® vaccine prior to enrollment or during the trial. Prior chemotherapy was allowed with a three week washout prior to trial enrollment. Comorbidities, including kidney disease with azotemia, liver disease or hepatic enzymopathy greater than twice the upper limit of basal state, or chronic infection were not allowed.
[0095] Prior to the start of therapy, dogs were evaluated by thoracic radiographs and draining lymph node aspirate for accurate staging. Abdominal ultrasound was performed at clinician discretion to evaluate for abdominal metastasis as indicated. Dogs underwent surgery at the start of the trial to resect the tumor, with clear margins where possible. Tumor cells were isolated from a portion of the tumor and treated with exoglycosidases and chemical oxidation procedures to remove carbohydrate functional groups (CFGs). Successful elimination of CFGs was confirmed by lectin binding analysis of the treated cells. The tumor cells were subjected to five freeze-thaw cycles to kill the cells and generate tumor cell lysates. The resulting lysate was mixed with AS04 adjuvant (alum, monophosphoryl lipid A) in physiological saline. Dogs were inoculated subcutaneously at different sites on their limbs with lysates from 7-10 X 106 cells at 0, 2, 4 and 6 weeks. Prior to the first vaccine administration, and at each subsequent administration, then monthly thereafter, blood was collected for humoral and cellular assays to evaluate tumor- specific immune response. Thoracic radiographs were repeated every 2 months until 6 months, then every 3 months thereafter. Draining lymph nodes was monitored by palpation and aspiration on the same schedule as thoracic radiographs are made.
[0096] None of the treated dogs developed adverse events following vaccination. As shown in Table 1, the metastasis was resolved in three of the four dogs. Of those three dogs, the average age of survival was 447 ± 108 days following diagnosis.
Caudal + + 10/15/
Mandible 8/5/14 IV Progressive 71
8/5/14 9/11/14 14
Melanoma
2 Left
Mandible + + II
2/04/1
Amelanoti 4/27/2015 progressed Resolved 646
5/1/15 8/12/15 7
c to IV
Melanoma
3 Left
Cervical
Lymph 12/15/201 +
- III Resolved Alive 423 Node 5 12/15/15
Metastatic
Melanoma
4
Right
05/23/201
Maxillary - - II None Alive 273
6
Melanoma
[0097] The description herein is merely exemplary in nature and, thus, variations that do not depart from the gist of that which is described are intended to be within the scope of the teachings. Such variations are not to be regarded as a departure from the spirit and scope of the teachings.
Claims
1. A composition comprising: a cancer cell lysate, wherein the cancer cell lysate comprises modified cancer cells that are characterized by having at least 50% of the carbohydrate functional groups thereon disrupted in comparison to a normal cancer cell from the same type of cancer as the modified cancer cell; and
at least one additional component selected from the group consisting of pharmaceutically-acceptable carriers, adjuvants, diluents, preservatives, antibiotics, and combinations thereof.
2. The composition of claim 1, wherein said additional component is an adjuvant.
3. The composition of claim 3, wherein said adjuvant is AS04.
4. The composition of claim 1, wherein the disrupted carbohydrate functional groups are no longer able to function as a glycan shield.
5. The composition of claim 1, wherein the quantity of modified cancer cells is
between 500,000 and 100,000,000.
6. The composition of claim 1, wherein the modified cancer cells are from a solid cancer.
7. The composition of claim 1, wherein the modified cancer cells are from a liquid cancer.
8. The composition of claim 1, wherein the modified cancer cells are from a Stage I, Stage II, Stage III, or Stage 4 cancer.
9. The composition of claim 1, further comprising a different cancer therapy or treatment.
10. The composition of claim 1, wherein the modified cancer cells are all from the same individual.
11. A composition comprising:
a quantity of modified cancer cells, wherein the cancer cells are characterized by having at least 50% of the carbohydrate functional groups thereon disrupted in comparison to a normal cancer cell from the same type of cancer as the modified cancer cell; and
at least one additional component selected from the group consisting of pharmaceutically-acceptable carriers, adjuvants, diluents, preservatives, antibiotics, and combinations thereof.
12. A method of treating cancer in a patient comprising the steps of:
obtaining a sample of cancer cells;
subjecting said cancer cells to a deglycosylating process wherein the cancer cells have at least 50% of the carbohydrate functional groups thereon disrupted in comparison to a normal cancer cell from the same type of cancer that has not been subjected to a deglycosylating process, thereby resulting in deglycosylated cancer cells;
lysing said deglycosylated cancer cells;
producing a cancer cell lysate from said lysed deglycosylated cancer cells; and
administering said cancer cell lysate to the patient.
13. The method of claim 12, wherein the cancer cell lysate is combined with at least one additional component selected from the group consisting of pharmaceutically-
acceptable carriers, adjuvants, diluents, preservatives, antibiotics, and
combinations thereof prior to administration to the patient.
14. The method of claim 13, wherein said at least one additional component is an adjuvant.
15. The method of claim 14, wherein said adjuvant is AS04.
16. The method of claim 12, wherein the sample of cancer cells comprises between 500,000 and 100,000,000 cancer cells.
17. The method of claim 12, further comprising the step of washing the cells after the deglycosylation process.
18. The method of claim 17, wherein the washed cells are resuspended in an aqueous buffer.
19. The method of claim 18, wherein said aqueous buffer comprises a gentle
oxidizing agent.
20. The method of claim 12, wherein said lysing is performed through a series of freeze/thaw cycles.
21. The method of claim 12, wherein the deglycosylating process comprises
incubating said cancer cells with at least one deglycosylating agent.
22. The method of claim 21, wherein the deglycosylating agent is selected from the group consisting of one or more deglycosylating enzymes, one or more glycosylation inhibitors, and combinations thereof.
23. The method of claim 12, wherein the cancer cells are from a solid cancer.
24. The method of claim 12, wherein the cancer cells are from a liquid cancer.
25. The method of claim 12, wherein the cancer cells are from a Stage I, Stage II, Stage III, or Stage 4 cancer.
26. The method of claim 12, further comprising the step of administering a different cancer therapy or treatment.
27. The method of claim 12, wherein the cancer cells are all from the same individual.
28. The method of claim 27, wherein the individual is the same individual receiving the administration.
29. The method of claim 12, wherein said administering step comprises intradermal administration.
30. The method of claim 12, wherein the administering step comprises multiple
administrations.
31. The method of claim 30, wherein there is at least two weeks between each
administration.
32. The method of claim 30, wherein there are four total administrations.
33. The method of claim 12, further comprising the step of a booster administration at least 6 months after the administration.
34. The method of claim 12, wherein said administering results in tumor growth
impairment of at least 5%.
35. The method of claim 12, wherein said administering results in tumors shrinking at least 5%.
36. The method of claim 12, wherein said administering results in at least a 5 %
reduction in the incidence of tumor markers.
37. The method of claim 12, wherein said administering results in at least a 5%
increase in life expectancy.
38. A method for treating metastatic cancer comprising the step of inoculating of a subject (human or other mammal) with autologous deglycosylated tumor cell lysates to evoke an immune-based antitumor response with a potency that is inversely correlated with the stage of the cancer and the age or immune status of said subject.
39. A method for preventing or greatly impeding the development of aggressive
cancer comprising the step of inoculating of a healthy subject (human or other mammal) with syngeneic or HLA class I negative deglycosylated metastatic tumor cell lysates to evoke a durable antitumor response directed against TAA.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17760642.3A EP3423088A4 (en) | 2016-02-29 | 2017-02-28 | Cancer immune-based therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662301298P | 2016-02-29 | 2016-02-29 | |
US62/301,298 | 2016-02-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017151655A1 true WO2017151655A1 (en) | 2017-09-08 |
Family
ID=59679117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/020004 WO2017151655A1 (en) | 2016-02-29 | 2017-02-28 | Cancer immune-based therapy |
Country Status (3)
Country | Link |
---|---|
US (1) | US10898563B2 (en) |
EP (1) | EP3423088A4 (en) |
WO (1) | WO2017151655A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050048588A1 (en) * | 2000-11-27 | 2005-03-03 | Emanuel Calenoff | Immunogenic cancer peptides and uses thereof |
US20100247571A1 (en) * | 2009-03-27 | 2010-09-30 | Academia Sinica | Methods and compositions for immunization against virus |
US20150176045A1 (en) * | 2013-12-18 | 2015-06-25 | Caliber Biotherapeutics, Llc | Method for in Vivo Production of Deglycosylated Recombinant Proteins Used as Substrate for Downstream Protein Glycoremodeling |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6017540A (en) * | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
US20020176845A1 (en) * | 1999-03-03 | 2002-11-28 | Frank W. Falkenberg | Compositions and methods for treatment of tumors and metastatic diseases |
US7098195B2 (en) * | 2001-11-28 | 2006-08-29 | Health Research, Inc. | Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells |
EP2471536A1 (en) * | 2004-09-29 | 2012-07-04 | Harbor BioSciences, Inc. | Steroid analogs and characterization and treatment methods |
FR2885525B1 (en) * | 2005-05-13 | 2009-09-18 | Urodelia Sa | MEDICAMENT PARTICULARLY ANTI-CANCER, FOR IMMUNOTHERAPY TREATMENT, PARTICULARLY AUTOLOGOUS |
WO2007150054A2 (en) * | 2006-06-24 | 2007-12-27 | Mrugesh Shah | Immunogenic compositions having altered glycosylations |
KR101568323B1 (en) * | 2014-01-08 | 2015-11-12 | 한국원자력의학원 | Composition for inducing maturation of dendritic cell comprising gelsolin and method of inducing the same |
-
2017
- 2017-02-28 US US15/445,576 patent/US10898563B2/en active Active
- 2017-02-28 WO PCT/US2017/020004 patent/WO2017151655A1/en active Application Filing
- 2017-02-28 EP EP17760642.3A patent/EP3423088A4/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050048588A1 (en) * | 2000-11-27 | 2005-03-03 | Emanuel Calenoff | Immunogenic cancer peptides and uses thereof |
US20100247571A1 (en) * | 2009-03-27 | 2010-09-30 | Academia Sinica | Methods and compositions for immunization against virus |
US20150176045A1 (en) * | 2013-12-18 | 2015-06-25 | Caliber Biotherapeutics, Llc | Method for in Vivo Production of Deglycosylated Recombinant Proteins Used as Substrate for Downstream Protein Glycoremodeling |
Non-Patent Citations (3)
Title |
---|
CLARK ET AL.: "Abstract 660: A Potential Immune Deviating Pathway that Protects Human Sperm and Aggressive Tumor Cells", 43RD ANNUAL MEETING OF SOCIETY FOR THE STUDY OF REPRODUCTION, 30 July 2010 (2010-07-30), Reston, pages 149 - 149, XP009512686, Retrieved from the Internet <URL:https://ssr.connectedcommunity.org/HigherLogic/System/DownloadDocumentFile.ashx?DocumentFileKey=53282c5a-639f-d675-5b74-b2f97fcf0e80&forceDialog=0> [retrieved on 20170418] * |
CLARK ET AL.: "The role of glycans in immune evasion: the human fetoembryonic defence system hypothesis revisited", MOL HUM REPROD, vol. 20, 15 September 2013 (2013-09-15), pages 185 - 99, XP055414950 * |
See also references of EP3423088A4 * |
Also Published As
Publication number | Publication date |
---|---|
US10898563B2 (en) | 2021-01-26 |
EP3423088A1 (en) | 2019-01-09 |
EP3423088A4 (en) | 2019-11-13 |
US20170246275A1 (en) | 2017-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mukherjee et al. | Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer | |
Jacobs et al. | An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma | |
AU2011248583B2 (en) | Immunogenic compositions and methods for treating neoplasia | |
AU2010200003B2 (en) | Tumor vaccine | |
EP1712238A1 (en) | Anthracyclin induced immunogenic dead or dying cells composition | |
US8062646B2 (en) | Tissue vaccines and uses thereof | |
US11590217B2 (en) | Neoepitope vaccine and immune stimulant combinations and methods | |
US9283266B2 (en) | Metastasis inhibition preparations and methods | |
Becker et al. | Mollusk hemocyanins as natural immunostimulants in biomedical applications | |
JP2014040429A (en) | Tumor vaccine | |
Wan et al. | The attenuated hepatocellular carcinoma-specific Listeria vaccine Lmdd-MPFG prevents tumor occurrence through immune regulation of dendritic cells | |
CN104136040B (en) | Autologous cancer cell vaccine | |
US10898563B2 (en) | Cancer immune-based therapy | |
WO2002094199A2 (en) | METHOD OF INCREASING ANTI-NeuGc ANTIBODY LEVELS IN BLOOD | |
JP6755012B2 (en) | Co-adjuvant composition and vaccine composition containing it | |
WO2009094387A1 (en) | Compositions and methods for inducing tumor resistance | |
WO2021071468A1 (en) | Neoepitope vaccine and immune stimulant combinations and methods | |
US20180117144A1 (en) | Targeted cytosolic delivery of antigenic compounds | |
Aysan et al. | Cancer preventive effects of whole cell type immunization against mice Ehrlich tumors | |
Zhou | Enhanced anti-tumor immunity by breaking immune tolerance | |
Cohen et al. | 4 Principles of Antitumor Immunity | |
Brown | An empirical framework for combining surgery with immune therapy | |
US20170072049A1 (en) | A Composition Comprising Ex-Vivo Generated Dendritic Cells | |
Veltman et al. | Research Article Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017760642 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017760642 Country of ref document: EP Effective date: 20181001 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17760642 Country of ref document: EP Kind code of ref document: A1 |